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Abstract 
The translocator protein (18 kDa) (TSPO) is a highly conserved, ubiquitous protein 
with a high affinity in binding cholesterol. Located in the outer mitochondrial 
membrane (OMM), TSPO has been discussed as the key protein for the cholesterol 
transport and therefore as a critical factor in steroidogenesis for a long time. Since 
recent in vivo and in vitro studies using TSPO knock-out models have been refuting 
its role in steroidogenesis, it is still an open question if TSPO is involved in 
neurosteroidogenesis. Furthermore, studies of the last two years started to 
characterize TSPO as a key protein in mitochondrial metabolism, assuming that 
TSPO has a regulatory function in calcium (Ca2+) homoeostasis, glucose 
homoeostasis, mitochondrial respiration and ROS (reactive oxygen species) 
production. In this thesis the link between TSPO and the regulation of mitochondrial 
metabolism and neurosteroid synthesis was analyzed to characterize a possible role 
of TSPO.  
In order to ascertain a possible involvement of TSPO in neurosteroidogenesis, a 
TSPO knock-down in mouse brain cells was performed to measure pregnenolone 
concentration as a precursor of neurosteroid synthesis by means of ELISA technique 
(enzyme-linked immunosorbent assay) and GC/MS (gaschromatography/mass 
spectroscopy). I was able to show that TSPO regulates neurosteroid synthesis of 
brain microglia cells.  
The regulatory function of TSPO in mitochondrial Ca2+ homoeostasis was analyzed 
by means of Ca2+ imaging via FURA-2 dye. The results showed no significant 
differences in Ca2+ homoeostasis of TSPO knock-down and scramble cells. Using 
drug treatment, both TSPO agonists XBD173 and PK11195 showed TSPO unrelated 
effects. Only LPS and Ro5-4864 treatment lead to the assumption that the presence 
of TSPO might be necessary to protect the cell from cell death under special 
conditions. 
Considering TSPO as a regulatory protein of the mitochondrial energy metabolism, 
the mitochondrial membrane potential was analyzed under different conditions using 
the ratiometric JC-1 dye. My results show a direct link between the TSPO knock-
down and the significantly reduced energy state of the cell. 
To further characterize TSPO as a regulator of the mitochondrial energy metabolism, 
the respiration was analyzed by means of High Resolution Respirometry via 
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Oxygraph O2k. As a result I found a direct link between TSPO knock-down and an 
increased maximal respiration indicating the high energy demand of the cell.  
This thesis describes the controversial role of TSPO in steroidogenesis according to 
new findings and characterizes the function of TSPO as a regulatory protein in 
neurosteroidogenesis. Moreover, this thesis presents new insights for TSPO as a 
regulatory protein in the mitochondrial metabolism.  
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Translation of the Abstract (German) 
Das Translokatorprotein (18 kDa) (TSPO) ist ein hochkonserviertes, ubiquitäres 
Protein mit einer hohen Bindungsaffinität gegenüber Cholesterol. TSPO, was in der 
äußeren Mitochondrienmembran lokalisiert ist, wurde lange Zeit als Schlüsselprotein 
für den Cholesterintransport und somit als kritischer Faktor für die Steroidsynthese 
diskutiert. Doch die jüngsten in vivo- und in vitro-Studien, die vor allem auf 
genetischen TSPO Knock-out Modellen basieren, widerlegen sehr eindeutig diese 
Rolle von TSPO als Schlüsselprotein in der Steroidsynthese. Dennoch ist es 
gegenwärtig nicht geklärt, ob TSPO an der Neurosteroidsynthese beteiligt sein 
könnte. Darüber hinaus begannen Forscher in den letzten zwei Jahren, TSPO als ein 
Schlüsselprotein auf einem neuen Gebiet, dem mitochondrialen Stoffwechsel, zu 
charakterisieren. Dabei wurde untersucht, ob TSPO eine regulatorische Funktion im 
mitochondrialen Stoffwechsel übernimmt. Darunter zählen unter anderem die 
Kalzium-Homöostase, der Blutzuckerstoffwechsel, die mitochondriale Atmung und 
die Entstehung reaktiver Sauerstoffspezies.  
In dieser Arbeit wurde die Verbindung zwischen TSPO und der Regulation des 
mitochondrialen Metabolismus sowie der Neurosteroidsynthese analysiert, um die 
Rolle von TSPO in diesem Gebiet zu charakterisieren. 
Um eine mögliche Beteiligung von TSPO an der Neurosteroidsynthese zu ermitteln, 
wurde ein TSPO-Knock-down in BV-2 Mikrogliazellen durchgeführt, um die 
Konzentration von Pregnenolon (Ausgangsstoff für die Neurosteroidsynthese) mittels 
ELISA-Technik (enzymgebundenes, antikörperbasierte Nachweisverfahren) und GC / 
MS (Gaschromatographie / Massenspektroskopie) zu bestimmen. Ich konnte zeigen, 
dass TSPO die Neurosteroidsynthese von BV-2 Mikrogliazellen reguliert. 
Um die regulatorische Funktion von TSPO in der mitochondrialen Kalzium-
Homöostase zu untersuchen, wurde der Kalzium Haushalt von BV-2 Scramble Zellen 
und BV-2-TSPO-Knock-down Zellen mittels eines Bildgebungs-Experimentes 
(Calcium Imaging via FURA-2-Farbstoff) analysiert. Die Ergebnisse zeigten keine 
signifikanten Unterschiede im Kalzium-Stoffwechsel von BV-2-TSPO-Knock-Down 
und BV-2 Scramble Zellen. Nach einer medikamentösen Behandlung mit 
ausgewählten Substanzen zeigten XBD173 und PK11195 (TSPO-Agonisten) 
lediglich TSPO-unabhängige Effekte. Nur die Ergebnisse der LPS- und Ro5-4864- 
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Behandlung führen zu der Annahme, dass die Anwesenheit von TSPO erforderlich 
ist, um die Zelle unter besonderen Bedingungen vor dem Zelltod zu schützen. 
Weiterhin wurde TSPO als regulatorisches Protein des mitochondrialen 
Energiestoffwechsels betrachtet. Dafür wurde das mitochondriale Membranpotential 
unter verschiedenen Bedingungen unter Verwendung des ratiometrischen JC-1-
Farbstoffs untersucht. Die Ergebnisse zeigen, dass ein TSPO-Knock-down mit einem  
reduzierten Energiezustand der Zelle (somit erhöhter Energiebedarf) einhergeht. 
Zur weiteren Charakterisierung des regulatorischen Einflusses von TSPO auf den 
mitochondrialen Energiestoffwechsel, wurde die mitochondriale Atmung mittels zwei 
verschiedenen Methoden, des hochauflösenden Respirometers Oxygraph O2k und 
des Seahorse Flux Analyzers analysiert. Als Ergebnis war eine direkte Verbindung 
zwischen dem TSPO-Knock-down und einer erhöhten maximalen Respiration zu 
erkennen, die wiederum mit dem hohen Energiebedarf der Zelle einhergeht. 
Diese Dissertationsarbeit untersucht und charakterisiert die Funktion von TSPO als 
regulatorisches Protein in der Neurosteroidsynthese und die darüber hinaus 
erlangten, neuen Erkenntnisse über TSPO als regulatorisches Protein im 
mitochondrialen Stoffwechsel.  
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1 TSPO 18kDa - a controversial protein of the OMM  
The discovery of TSPO as an alternative binding site for the benzodiazepines in 1977 
resulted in being named the peripheral benzodiazepine receptor (PBR) (Braestrup & 
Squires, 1977). The versatile TSPO expression throughout the entire body (Li et al., 
2015) and the early discovery as a high-afﬁnity cholesterol binding protein in the 
OMM (Li & Papadopoulos, 1998) established a link between TSPO, cholesterol 
transport and biosynthesis of steroids (Papadopoulos et al., 1997); (Rupprecht et al., 
2010). Papadopoulos et al. described TSPO as an essential component of the 
cholesterol transport across the mitochondrial membrane, thereby providing the rate-
limiting step of steroid production. Thus, almost 30 years after its discovery the PBR 
was renamed into Translocator protein 18 kDa (TSPO 18kDa) due to the new 
findings about its molecular function in cholesterol translocation (Papadopoulos et al., 
2006). For a long period of time TSPO was discussed as the critical factor in 
steroidogenesis and TSPO knock-out in mice were reported as being 
early embryonically lethal (Papadopoulos et al., 1997). This believe based on a 
single study from 1997, using TSPO whole-body knock-out mice, unfortunately this 
study did neither provide any details about the used methods nor about the design of 
the knock-out mice (Papadopoulos et al., 1997). Recently, TSPO as the key player in 
steroid synthesis has been called into doubt. Kelly-Hershkovitz et al. indicated in 
1998 the very first assumptions of steroid synthesis underlying TSPO function may 
be incorrect, requiring further examination (Kelly-Hershkovitz et al., 1998). More 
recent studies using global KO mice or steroidogenic-tissue-specific KO mice 
revealed unexpected results: a genetic TSPO deficiency or loss has no effects on 
steroid biosynthesis (Morohaku et al., 2014) or embryonic growth nor does it lead to 
phenotypic abnormalities (Tu et al., 2014); (Banati et al. 2014). Most surprisingly was 
the examination of a human adrenal cell line which did not express endogenous 
TSPO, but was still competent in producing steroids (Tu et al, 2014). This led to a 
reappraisal of TSPO's biological role in steroid synthesis and its importance 
throughout the body (Selvaraj & Tu, 2016).  
1.1 Expression of TSPO 
TSPO 18 kDa is a highly conserved protein found in every organ of mammals (Anholt 
et al., 1985) and also in bacteria (Yeliseev & Kaplan, 1995). However, the particularly 
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highest expression levels have been found in steroid-synthesizing cells and tissues of 
adrenal glands, gonads, placenta, testis (De Souza et al., 1985) (Papadopoulos et 
al., 2006). This was basically the link of numerous studies attempting TSPOs function 
to steroidogenesis (Papadopoulos et al., 1997), undermining that TSPO is not solely 
expressed in steroid-synthesizing cells or tissues. An abundant TSPO expression 
was found in cells and tissues which do not produce steroids such as heart, kidney 
(Gehlert et al., 1985), lung, liver, spleen and bone marrow (Anholt et al., 1985) 
suggesting a broader function for this protein.  
TSPO expression in the CNS is extremely weak (Daugherty et al., 2013) and focused 
on microglia (Casellas et al., 2002) and reactive astrocytes (Maeda, et al., 2007). The 
expression levels in the CNS, primarily in brain microglia cells (Banati et al., 1997) 
readily increase when exposed to pathological stressors or physicochemical 
abnormalities (Rupprecht et al., 2010). For over 20 years, TSPO has been used as 
an imaging biomarker of active disease or disease-related tissue (Liu et al., 2014a). 
Therefore, radiolabeled TSPO ligands are used in positron emission tomography 
(PET) to image the increased TSPO expression in areas of neuroinflammation in vivo 
in patients with brain diseases (Vivash & O'Brien, 2016).  
More precisely, TSPO is an integral membrane protein of 169 amino acids located at 
the contact sites between the outer (OMM) and inner mitochondrial membrane (IMM) 
(Anholt et al., 1986). However, its expression has also been reported in the nucleus 
(Hardwick et al., 1999) and on the erythrocyte membrane (Olson et al., 1988) 
whereby none of these two alternative localizations have been verified. Due to its 
localization in the mitochondrial membrane TSPO is now thought to partake in the 
regulation of mitochondrial functioning (Gatliff & Campanella, 2012); (Selvaraj & Tu, 
2016). 
1.2 TSPO structure and resulting functions 
In 1993 a TSPO 3D structure was modeled, deriving from a seven-transmembrane 
rhodopsin structure, which was almost the only membrane protein structure available 
at this time. This 3D structure spanned only one mitochondrial phospholipid layer 
(Bernassau et al., 1993). Later, a murine TSPO protein structure replaced the early 
model and described the presence of at least five-alpha-helical transmembrane 
segments (Murail et al., 2008). Two years later, an electron cryo-microscopy study 
revealed a five-transmembrane structure of Rhodobacter sphaeroides TSPO 
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(RsTSPO) (Korkov et al, 2010) which is assumed to build TSPO homo dimers. This 
model favored speculations about TSPO acting as a channel with a hydrophobic 
interior core, lined by the cholesterol-binding CRAC (cholesterol-
recognition amino acid consensus) motif. This aspect underlined the assumption of 
TSPO playing a role in translocation of lipophilic substrates – especially cholesterol – 
across the OMM thereby representing the rate-limiting step in steroidogenesis 
(Rupprecht et al., 2010). 
The most recent 3D high-resolution structure of mammalian TSPO was obtained by 
means of nuclear magnetic resonance (NMR) technique whereupon TSPO was 
reconstituted into dodecylphosphocholine (DPC) micelles and complexed with its 
high-affinity ligand PK11195 (Jaremko et al., 2014). This study of Jaremko et al. 
opened new perspectives in TSPO structure (Jaremko et al., 2014). 
1.3 Recent TSPO structure 
The TSPO structure comprises 169 amino acids which are organized in five 
transmembrane helices (TM1 to TM5) tightly packed in a clockwise order TM1-TM2-
TM5-TM4-TM3 when viewed from the cytosol (Jaremko et al., 2014). The loops 
between the transmembrane helices are short, with the exception of the TM1-TM2 
loop (Jaremko et al., 2014). Because of the high sequence conservation of TSPO, 
the topology of the structure is likely to be retained in other mammalian species as 
well as bacterial homologs (Jaremko et al, 2014).  
The TSPO structure also owns an N- and a C-terminal tail, whereby the C-terminus in 
TM5 is equipped with the cholesterol-recognition amino acid consensus (CRAC) 
motif binding cholesterol in nanomolar concentration (Jamin et al., 2005). The 3D 
structure of Jaremko et al. revealed that the side chain including CRAC motif do not 
form a channel-like core for cholesterol binding and translocation as previously 
assumed (Rupprecht et al., 2010), rather they are located on the outside of the TSPO 
structure pointing towards the membrane area. 
Furthermore, they investigated a highly positive charge of the CRAC motif side chain 
and positively and negatively charged patches on the IMS side of the receptor. These 
different charged areas on the extra- and intra-mitochondrial side might be important 
for recognition of endogenous ligands and proteins interacting with TSPO (Jaremko 
et al, 2014).  
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All these findings indicate a fundamental doubt in the ability of TSPO to form a 
cholesterol translocating channel. Jaremko et al. attempted to explain this 
phenomenon by the (already known) ability of cholesterol to dimerize (Harris, 2010) 
which further may modulate the oligomerization of TSPO thereby forming a channel. 
This assumption was based on a study of several transporters which function as 
dimers (Morrison & Henzler-Wildman, 2012). Furthermore, a TSPO oligomerization 
was demonstrated through covalent tyrosine cross-links under unique circumstances, 
rather than based on cholesterol dimerization (Delavoie et al., 2003). 
The most recent study about TSPO structure demonstrates that the amino acids 
N158–S159, which are part of the cholesterol binding CRAC motif are disordered in 
the absence of PK11195, but show a stable helical conformation upon PK11195 
binding. Further, it is assumed that a conformational stabilization of the CRAC motif 
might influence the interaction of mammalian TSPO with cholesterol. However, a 3D 
structure of TSPO in complex with cholesterol is not available to date and it is 
unknown if cholesterol binding might vice versa modulate binding of ligands to a 
binding site (Jaremko et al., 2015b). 
1.4 TSPO ligands 
TSPO ligands have a potential for diagnostic and therapeutic applications which 
makes TSPO a topic of natural interest for pharmacologists (Arbo et al., 2015). The 
best-characterized synthetic ligand of TSPO is the isoquinoline carboxamide 
PK11195 (N-butan-2-yl-1-(2-chlorophenyl)-N-methylisoquinoline-3-carboxamide), 
which binds to TSPO with nanomolar affinity in many species (Fur et al., 1983); 
(Owen & Matthews, 2011). PK11195 is used as a TSPO ligand in positron emission 
tomography to visualize brain inflammation in patients with neuronal damage (Owen 
& Matthews, 2011).  The binding was found to be in a 1:1 stoichiometry between 
TSPO and PK11195 and is described as a binding pocket formed by TSPOs five 
transmembrane helices in the upper cytosolic part of the helical bundle (Jaremko et 
al., 2014). Additionally, it is already known, that the PK11195 ligand-binding site is 
flexible and instable in the absence of PK11195 binding, but stabilized in a rigid and 
stable conformation when PK11195 is bound (Jaremko et al., 2015b).  Interestingly, 
PK11195 is able to inhibit the neurosteroid-inducing effects of other TSPO binding 
drugs like FGIN-1-27 (Korneyev et al., 1993), indoleacetamides (Kozikowski et al., 
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1993), YL-IPA08 (Zhang et al., 2014), CB-34 (Serra et al., 1999), and TTN (Do-Rego 
et al., 1998). 
Another predominantly investigated synthetic TSPO ligand is the diazepam derivate 
Ro5-4864 (7-Chloro-5-(4-chlorophenyl)-1-methyl-3H-1,4-benzodiazepin-2-one) which 
also binds TSPO with nanomolar afﬁnity, whereby the binding affinity is higher for 
PK11195 (Kd < 20 nM) (Fur et al., 1983). It was former known as a convulsant 
(Weissmann et al., 1983) and anxiogenic substance (File & Lister, 1983) and was 
discussed as a TSPO agonist (Fur et al., 1983), (Selvaraj & Tu, 2016). Now it is used 
as a potent imaging ligand (Weissmann & Raveh, 2003) and recently assumed to be 
a neuroprotective agent (Palzur et al., 2016).  
In the last 25 years, additional TSPO ligands, such as alpidem, have been 
developed. They also bind to both TSPO and the GABAA receptor. Alpidem was 
already officially admitted for anxiety treatment from 1991-1994, but was finally 
withdrawn due to leading to liver dysfunction with severe or even lethal 
consequences (Baty, et al., 1994). There might be a significant correlation between 
these side effects and the GABAA receptor binding in liver tissue (Langer et al., 
1990). DAA1106 is another selective TSPO ligand binding with sub-nanomolar 
affinity (Venneti et al., 2007). There are many more synthetic ligands (Rupprecht et 
al., 2010), most of which have been developed as neuroimaging agents and 
diagnostic tools, used to detect regions of neuroinflammation, correlating with various 
neuronal pathologies (Chauveau et al., 2008). XBD173, also termed as AC-5216 or 
emapunil, is a selective TSPO phenylpurine ligand. XBD173 is known to bind with 
high affinity to TSPO, thereby exerting anxiolytic, antidepressive, and neuroprotective 
effects (Kita et al., 2009), (Kita et al., 2004), (Qui et al., 2013). Another established 
TSPO ligand is the benzoxazine etifoxine, which also binds with a high affinity to 
TSPO, thereby stimulating neurosteroid synthesis (Verleye et al., 2005), (Wolf et al., 
2015). Etifoxine is not only selective for TSPO, but also binds to GABAA receptors 
(Hamon et al., 2003). The anxiolytic etifoxine effect may result from direct targeting 
GABAA receptors (Nguyen et al., 2006). 
Furthermore, several endogenous ligands for TSPO exist, such as diazepam-binding 
inhibitors (DBIs), porphyrins and cholesterol. The TSPO amino acid sequence 
consists of the cholesterol-binding amino acid consensus (CRAC) motif suggesting a 
molecular mechanism for cholesterol binding and/or transport (Li et al., 2001). This 
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led to a model of TSPO as a cholesterol transport channel in the OMM playing an 
indispensable role in steroidogenesis (Papadopoulos et al., 1997).  
In 1991, TSPO was reported to interact with the diazepam-binding inhibitor (also 
known as the Acyl-CoA binding protein/ACBP), which was assumed to stimulate 
steroid production at very modest levels (Papadopoulos et al., 1991). DBIs bind with 
micromolar affinity to both TSPO and the GABAA receptor.  
Porphyrins, which are tetrapyrrolic pigments and important in heme biosynthesis 
pathways, are considered endogenous ligands binding TSPO (Verma et al.1987). 
The highly conserved porphyrin binding property of TSPO (Zhao et al., 2016) was 
initially assumed to partially rescue cells from porphyrin induced phototoxicity 
(Ratcliffe & Matthews, 1995). Although the ability of PPIX binding to TSPO remains 
unchanged, recent studies using TSPO knockout mice/cell lines have established 
that TSPO plays no critical physiological role related to PPIX and heme biosynthesis 
(Banati et al. 2014; Zhao et al. 2016).  
2 New perspectives for TSPO  
In regard to the above-mentioned experimental observations of the last three years 
the role TSPO in steroidogenesis is questionable. As various TSPO knock-out 
studies allowed deeper insight in TSPO function, a genetic TSPO deletion does not 
affect steroidogenesis (Morohaku et al., 2014), (Tu et al.,  2014), (Banati et al., 2014), 
(Šileikytė et al., 2014). Moreover, these observations led in the assumption that 
previous pharmacological effects on steroidogenesis, mostly obtained by the use of 
TSPO ligands, could be unspecific or unrelated to TSPO (Tu et al., 2015), (Šileikytė 
et al., 2014). Although these early ligand studies helped to figure out structural, 
biochemical and pharmacological information, the precise physiological and 
pathological function is still unknown (Selvaraj & Stocco, 2015), (Gatliff & 
Campanella, 2016), (Selvaraj & Tu, 2016).  
Since these TSPO knock-out models refuted the role of TSPO in steroidogenesis, 
there is still an open question of TSPO involvement in neurosteroidogenesis (Selvaraj 
& Tu, 2016). Additionally, there is some indication for a role of TSPO in calcium 
homoeostasis (Gatliff & Campanella, 2012), mitochondrial respiration (Banati et al., 
2014), stress response in relation to ROS (Gatliff et al., 2014) and other bioenergetic 
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parameters reflecting mitochondrial health (Gatliff & Campanella, 2016), (Tu et al., 
2016).  
2.1 TSPO in neurosteroid synthesis of brain mitochondria  
Steroid biosynthesis is mainly performed by adrenal, gonads, placenta, thymus, skin 
and brain. In these tissues mitochondria are able to produce steroids de novo from a 
precursor molecule. While it is known that e.g. both, adrenal and gonadal steroid 
production is regulated by hormones, there is still no evidence for hormone regulation 
in neurosteroid  synthesis (Papadopoulos, 2014).  
The precursor molecule of the neurosteroid synthesis is cholesterol (figure 1). As a 
free molecule, it is located in various intracellular stores e.g. the endoplasmatic 
reticulum (ER). However, it can also be found in cellular membranes as structural 
cholesterol. The slightly water-soluble molecule needs special mechanisms to get 
from intracellular stores to the OMM, where it stays segregated from structural 
cholesterol. Cholesterol is then being transported from the OMM to cytochrome P450 
CYP11A1 in the inner mitochondrial membrane (IMM) (Papadopoulos, 2014) which 
mediates a conversion from cholesterol to pregnenolone (figure 1). 
In a further step, pregnenolone, the precursor of all neurosteroids, is enzymatically 
metabolized into progesterone. Progesterone, on the one hand is metabolized by 5α-
reductase into 5α-dihydroprogesterone (5α-DHP) and afterwards converted into 
allopregnanolone (3α,5α-THP) by 3α-hydroxysteroiddehydrogenase (3α-HSD). On 
the other hand, progesterone is also metabolized into deoxycorticosterone (DOC) by 
21-hydroxylase followed by a 5α-reductase oxidation into 5α-
dihydrodeoxycorticosterone (5α-DHDOC). Then, a 3α-hydroxysteroiddehydrogenase  
(3α-HSD) converts 5α-DHDOC into tetrahydrodeoxycorticosterone (THDOC) (figure 
1).  Both, allopregnanolone and THDOC are neurosteroids acting on the GABAA 
receptor, thereby causing in vivo anxiolytic effects (Stoffel-Wagner, 2003), (Pinna et 
al., 2006).  
Since more than half a decade, researchers have been trying to figure out the exact 
mechanism transferring cholesterol from intracellular stores to OMM, moving 
cholesterol from OMM to  IMM, and finally connecting cholesterol with 
CYP11A1.However, today still no specific mechanism is known to carry out all these 
steps. Only a few proteins have been discovered, which may work together in a large 
protein complex and may perform these functional steps.  
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Figure 1 The role of TSPO in neurosteroid synthesis. TSPO is hypothetically associated with other 
proteins such as VDAC (voltage dependent anion channel) and ATAD3A (AAA domain containing 3A) in 
the IMM (inner mitochondrial membrane). Cholesterol binds to the CRAC Domain of TSPO and is then 
translocated to the IMM. This translocation only works through a multi protein complex 
(transducteosome) with VDAC and the mitochondrial matrix protein ATAD3A. The mechanism in detail is 
still under investigation. Cholesterol is then metabolized to pregnenolone by CYP11A, which is the 
neurosteroid precursor molecule.  
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This hypothetical protein complex includes the steroidogenic acute regulatory protein 
(StAR), the translocator protein 18kDa (TSPO), and the voltage-dependent anion 
channel (VDAC) (Papadopoulos, 2014). For a long time, TSPO was considered to 
form a channel (Rupprecht et al., 2010) promoting the transport of cholesterol into the 
mitochondrial matrix, the rate-limiting step in neurosteroid synthesis. The early crystal 
structure of TSPO, which explains the role of TSPO in cholesterol transport as a kind 
of sliding mechanism, was discovered by new investigations. This sliding mechanism 
through the external protein surface requires the association of TSPO with other 
proteins (Li et al., 2015).  
Rone et al. hypothesized the cholesterol transfer through a complex named the 
“transduceosome”. In this transduceosome, cytosolic StAR pushes the cholesterol 
transport to OMM by interacting with OMM proteins such as TSPO and VDAC (Bose 
et al., 2002). Afterwards, the cholesterol transfer from OMM to IMM is supposed to be 
accomplished via a bridging complex between the VDAC in the OMM and adenine 
nucleotide translocase (ANT) in the IMM (Thomson, 2003). In a later study, blue 
native page analysis on steroidogenic tissue mitochondria identified two protein 
complexes, namely a 66 kDa and an 800 kDa protein complex, both binding 
cholesterol. A breakdown of these complexes provided the evidence that the 800 
kDa protein complex contains the OMM components of the transduceosome: TSPO, 
VDAC, the matrix protein ATAD3A and the IMM protein CYP11A; but not ANT, as 
supposed before (Papadopoulos et al., 2015). The experimental addition of StAR 
protein to this 800 kDa complex resulted in an increase of cholesterol binding and an 
increase in steroid formation. Consequently, StAR was required to initiate the 
transport of cholesterol to the IMM and VDAC might act as an anchor for TSPO and 
StAR. The matrix protein ATAD3A is assumed to form the bridge between OMM and 
IMM, which allows cholesterol to access to CYP11A1 in the IMM (figure 1) (Rone et 
al., 2012).  The 66 kDa protein complex consists of TSPO and other proteins. In case 
of being stimulated, TSPO assembles to trimers and associates with the 800 kDa 
complex, where it is then co-located with VDAC. The StAR protein gathers 
cholesterol and induces the binding to TSPO.  From there, cholesterol is translocated 
to the IMM through the formation of a contact site by VDAC and the mitochondrial 
matrix protein ATAD3A present in the 800 kDa complex. Cholesterol is then 
metabolized to pregnenolone by CYP11A1 (also present in the IMM part of the 800 
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kDa complex), supported by the electron transfer proteins ferredoxin and ferredoxin 
reductase. This forms the mitochondrial metabolon (Rone et al., 2012). 
Some studies found ANT to be the bridging protein which forms a contact site 
between OMM and IMM proteins to transport cholesterol (Thomson, 2003). However, 
it was shown in MS (mass spectroscopy) and FRET studies (fluorescence resonance 
energy transfer studies, which are used to determine if two fluorophores are within a 
certain distance to each other) (Rone et al., 2012) that ANT is not part of the protein 
complex, which promotes cholesterol transport and steroid formation. ATAD3A, 
which is located in the OMM, bridges the OMM and IMM and forms a contact site 
(Gilquin et al., 2010). A knockdown of this protein decreases steroid production 
assuming that cholesterol can neither pass the intermembrane space nor reach the 
IMM (Rone et al., 2012). The long isoform of ATAD3A, which may connect with other 
organelles such as the endoplasmic reticulum (ER) may form mitochondria-ER 
contact sites (Hubstenberger, 2008). These contact sites, termed “mitochondria 
associated membranes” (MAMs), play an important role in the transfer of lipids such 
as cholesterol. MAMs may establish a link between CYP11A1 and the site of 
cholesterol biosynthesis in the ER. VDAC also plays a role in MAM formation as it 
interacts with the inositol-1,4,5-triphosphate receptor in the ER, which is responsible 
for Ca2+ transfer. Studies showed that increased Ca2+ concentration in the matrix 
regulates the enzymes of the Krebs cycle. Especially isocitrate dehydrogenase is 
found in both, the 66 kDa and 800 kDa mitochondrial complexes, further providing 
nicotinamide adenine dinucleotide phosphate (NADPH). NADPH is used by 
ferredoxin reductase for the electron transport chain for CYP11A1 activity (Bernadi 
P., 1999). Further, this increased activity augments ATP production which is 
necessary for ATAD3A and mitochondrial function (Rone et al., 2012). 
2.2 TSPO in mitochondrial Ca2+ homoeostasis 
It was already shown in 1960 that isolated mitochondria are able to accumulate Ca2+ 
(Vashington & Murphy, 1962). Since it is known that mitochondria act at some 
neuronal synapses to store Ca2+ or release Ca2+ persistently from the mitochondrial 
matrix, brain mitochondrial Ca2+ signaling receives more attention. Thereby 
mitochondria contribute to neurotransmitter release from the presynaptic site (Jonas, 
2006). Moreover, Ca2+ excess in cellular or mitochondrial space triggers apoptosis. 
Ca2+ operates as an important second messenger regulating a variety of cellular 
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functions such as contraction, secretion, metabolism, gene expression, cell survival 
and cell death (Berridge M. J., 2012).  
During mitochondrial Ca2+ accumulation under physiological conditions, mitochondria 
have just a 10 – 30 nanometer distance to the ER resulting in close proximity to the 
IP3R receptors of the ER (Rizzuto et al., 1998).  
High levels of IP3R and SERCA have been found in the ER at these special contact 
sites to mitochondria creating Ca2+ micro domains. On the mitochondrial side, VDAC 
may perform the Ca2+ uptake in mitochondria (Gincel et al., 2001). The proven 
correlation between VDAC expression level and the transfer efficiency of Ca2+ micro 
domains from the ER to mitochondria relies on studies showing that VDAC 
overexpression increases Ca2+ permeability at ER-mitochondria contact sites, 
mitochondrial Ca2+ accumulation, and Ca2+ transfer between the two organelles 
(Rapizzi et al., 2002). VDAC is also co-located with IP3R’s and the glucose-regulated 
protein 75 (Grp-75) as a complex at the ER-mitochondria contact sites. This is 
possibly the link between VDAC and IP3R (Szabadkai et al., 2006). 
With regard to these findings, the mitochondrial Ca2+ accumulation and release under 
conditions of a direct ER-mitochondria link is possible, but there are still unknown 
participants. TSPO could have an outstanding role as a linking position, closely 
located to VDAC at the ER-mitochondria contact sites (Gatliff & Campanella, 2012). 
Recently, there is only little evidence that TSPO plays an important role in the Ca2+ 
homoeostasis: 
It has been shown that TSPO is also expressed in mitochondria of human colon 
cancer cells (HT-29). The high-affinity TSPO ligand PK11195 promotes a rapid 
intracellular Ca2+ increase in a dose-dependent manner. This increase is unaffected 
by extracellular Ca2+ and flunitrazepam (a partial TSPO agonist and inhibitor of 
TSPO’s cholesterol transport function). Ostuni et al. assumed this PK11195-induced 
Ca2+ increase as an indicator for the involvement of TSPO in the process of elevating 
the Ca2+ concentration (Ostuni et al., 2007). However, flunitrazepam is only a partial 
agonist for TSPO. Moreover, a role for TSPO regulating Ca2+ homoeostasis has been 
figured out in isolated rat heart mitochondria. Protoporphyrin IX (PPIX), a high-affinity 
TSPO ligand, decreases mitochondrial Ca2+ uptake dose-dependently. Another study 
by the same group showed PPIX affecting the function of VDAC. A VDAC-TSPO-
ANT complex reconstruction into lipid bilayers, which was then exposed to PPIX, 
showed decreased VDAC conductance. This finding provides first evidence that 
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TSPO may modulate mitochondrial Ca2+ homeostasis, and thereby other 
mitochondrial processes (Tamse et al, 2008). 
2.3 TSPO in mitochondrial respiration 
While only 2% of the total body weight is occupied by our brain, the brain requires up 
to 20% of the energy - even in the resting state. This energy is necessary for the 
neurotransmitter inclusion in synaptic vesicles, the presynaptic vesicle transfer and 
the postsynaptic signaling (Ly et al., 2006). Furthermore, energy is used for the 
maintenance of ion gradients across neuronal membranes, intracellular signaling and 
gene transcription as well as epigenetic gene regulation (Mattson et al., 2008). 
Being the main producers of energy in form of ATP, mitochondria are the 
powerhouse of the cell (Campanella et al., 2009). 
The first step of aerobic respiration is the aerobic glycolysis of glucose into pyruvate 
and the conversion of fatty acids into fatty-acyl-CoA. Due to this permeability of the 
OMM, pyruvate and fatty-acyl-CoA are transferred to the mitochondrial 
intermembrane space (IMS) and then imported into the mitochondrial matrix (Lodish 
et al., 2013). In the mitochondrial matrix, the pyruvate and fatty-acyl-CoA are 
converted into acetyl CoA, which is necessary to drive the citric acid cycle (Lodish et 
al., 2013). The electrons, gathered from this conversion are then moving through a 
series of IMM bound electron carriers, called electron transport chain (ETC) to O2, 
thereby regenerating NAD+ and FAD (Lodish et al., 2013). This stepwise movement 
of electrons is coupled to a proton (H+) pumping activity across the inner membrane, 
which results in an electrochemical H+ gradient crossing the IMM (Lodish et al., 
2013).  
The gradient forms a proton motive force which powers ATP synthesis and generates 
most of the ATP resulting from aerobic oxidation of glucose (Lodish et al., 2013). The 
proton motive force (pmf) across the IMM depends on a combination of two factors, a 
pH gradient and a membrane potential (∆ψm). The pmf is necessary for oxidative 
phosphorylation (OXPHOS), electron transport and ATP formation (Lodish et al., 
2013).  
On their way from NADH and FADH2 to the electron acceptor O2 electrons pass four 
large multiprotein complexes.These complexes form the ETC (Gatliff et al., 2012). 
Energy sourced from the ETC is used to pump protons outward the matrix generating 
the pH gradient and the membrane potential (Lodish et al., 2013). As described by 
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Peter Mitchell in his chemiosmotic hypothesis, the proton-motive force is the ultimate 
source of energy for ATP synthesis. The enzyme, which ensures the ATP production, 
ATP synthase or F0F1 complex, is highly conserved across species (Lodish et al., 
2013).  
Findings of VDAC reconstitution into planar phospholipid membranes provide 
compelling evidence that voltage-gating via VDAC selectively controls ATP/ADP flow 
between mitochondria and cytosol (Colombini, 2012). VDAC voltage-gating also 
controls the mitochondrial import of inorganic phosphate (Hodge & Colombini, 1997). 
As a result it is assumed that VDAC facilitates the transport of ADP, ATP, respiratory 
substrates, inorganic phosphate, organic anions as well as small cations like K+, Na+ 
and Ca2+ thereby enabling the mitochondrial function and energy supply (Lemasters 
& Holmuhamedov, 2006). However, the regulatory mechanisms of VDAC remain 
controversial. A long missing player in the regulation of VDAC’s OMM permeability 
was tubulin, a cytoskeleton protein. Carre et al. showed an association of 
mitochondrial tubulin with VDAC. It has already been published that, depending on 
VDAC`s phosphorylation state and applied voltage, nanomolar concentrations of 
dimeric tubulin induce functionally important reversible blockage of VDAC 
reconstituted into planar phospholipid membranes (Carre et al., 2002). A later 
analysis demonstrated that the VDAC-blocked state is impermeable to ATP and other 
multi-charged anions (Rostovtseva et al., 2012) and it reduces the respiration rate 
(Rostovtseva et al., 2008). According to this, the tubulin-VDAC interaction can be 
regulated through a competition with other proteins, correlated to VDAC (Gatliff & 
Campanella, 2012). An example for this is the OMM protein TSPO, localized in close 
proximity to VDAC, and prevalent at IMM-OMM contact sites. In primary microglia 
TSPO knock-out cells it has been demonstrated that the basal oxygen consumption 
was significantly reduced in comparison to wild-type cells. Consequently, TSPO 
might function as a modulator of cellular energy metabolism (Banati et al., 2014).  
There is evidence demonstrating TSPO’s involvement in mitochondrial metabolism. 
The respiration of mouse C1300 neuroblastoma cells was analyzed using TSPO 
ligands. In a study cells were incubated with Ro 5-4864 and PK11195 which resulted 
in a dose dependent reduction of oxygen consumption in these cells (Larcher et al., 
1989).  
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Another group isolated rat kidney mitochondria to treat each sample 24h with nine 
different TSPO ligands to investigate the respiratory function. The applied TSPO 
ligands, in particular Ro 5-4864 and PK11195 decreased the rate of oxidative 
phosphorylation (OXPHOS, triggered by addition of ADP) and increased the rate of 
state IV respiration (the rate arising when all available ADP is phosphorylated to 
ATP) (Hirsch et al., 1989). As a result, these findings corroborate a mitochondrial 
energy metabolism model in the outer mitochondrial membrane. In this model TSPO 
might interact with VDAC, altering VDAC permeability to ADP, Pi and ATP (Gatliff & 
Campanella, 2012). 
Recent studies using cells or mitochondria of genetic TSPO knock-out mice achieved 
different results. Šileikytė et al. compared the oxygen consumption rates (OCRs) 
of mitochondria from liver-specific Tspoc∆/∆ mice and control Tspofl/fl mice which 
showed no differences in the OCR’s of those cells (Šileikytė et al., 2014). Another 
group analyzed the OCR of embryonic fibroblasts from Tspo -/- mice which showed 
decreased values compared to Tspo fl/fl mice (Zhao et al. 2016). Tu et al. showed that 
the OCR in steroidogenic MA-10 leydig cells (expressing very high levels of TSPO) 
showed no difference when compared to TSPO-deleted MA-10 cells (Tu et al. 2016). 
First evidence of a TSPO oxygen regulation in brain cells was found in isolated 
primary microglia cells of TSPO knock-out mice. The OCR was significantly lower 
in TSPO knockout cells compared to control microglia (Banati et al. 2014). 
These studies indicate that the change in OCR is a cell-type dependent effect which 
might correlate with the energetic status of cell, mitochondrial ion signaling or ROS 
damage. Interestingly, mitochondria of brain cells were particularly affected by TSPO 
knock out (Banati et al. 2014), indicating a special role of TSPO in brain microglia 
metabolism.  
2.4 TSPO in mitochondrial energy metabolism, inflammation and protection 
With regard to several recent studies indicating that TSPO has no physiological 
function in steroidogenesis raises the critical question of the reason for its high 
expression level in mitochondria of steroidogenic tissue. Tu et al. identified TSPO 
affecting fatty acid oxidation (FAO) by investigating different mitochondrial properties 
in TSPO-deficient steroidogenic MA-10 cells. Further they observed an up-regulation 
of genes involved in mitochondrial FAO in the adrenal glands of TSPO knock-
out mice. These recent findings might indicate a novel TSPO function in modulating 
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mitochondrial metabolism which is important for lipid storage and metabolism (Tu et 
al., 2016). Moreover, the recent increase in obesity research and the associated use 
of quantitative trait loci analysis between inbred mouse strains identified TSPO 18 
kDa as one of the 6 possible genes which are able to influence mice triglyceride 
metabolism (Leduc et al., 2011).  
Not only for lipid metabolism, but also for the whole energy metabolism, maintained 
through the ETC, TSPO is important. Liu et al. successfully transfected TSPO in 
Jurkat cells which show a low to absent endogenous TSPO expression. They figured 
out that a set of genes which is involved in the ETC of mitochondrial energy 
production are up-regulated in the transfected Jurkat cells. Furthermore, this up-
regulation correlates with an increased mitochondrial ATP synthesis and an increase 
in cell excitability by decreased rectified K+ channel currents and with an increase in 
cell proliferation and motility. This increased cell metabolism, energy production, cell 
cycle, motility and cell membrane excitability is assumed by the regulatory effect of 
TSPO (Liu et al., 2017). 
Furthermore, TSPO is linked to inflammatory bowel diseases (IBL). Ostuni et al. early 
showed a TSPO overexpression in ulcerative colitis and Crohn’s disease and 
dysplasia (Ostuni et al., 2010). In 2016 the same group found a TNF-induced 
interleukin (IL)-8 expression induces reactive oxygen species (ROS) production and 
is followed by TSPO expression. TNF also alters mitochondrial ultrastructure thereby 
inducing apoptotic cell death. PK11195 treatment maintained the mitochondrial 
ultrastructure, prevented IL-8 and ROS production and thus the cell death (Issop et 
al., 2016). This assumes a TSPO function in mitochondrial membrane integrity, the 
control of mitochondrial ROS production and probably in tissue regeneration. 
A lot of studies characterized TSPO as a target which prevents ROS production, 
thereby preventing mitochondria induced cell death. This makes TSPO a particularly 
interesting drug target for future investigations (Veenman et al., 2008), (Gatliff et al., 
2014), (Selvaraj & Stocco, 2015), (Gut P., 2015), (Joo et al., 2015), (Tu et al., 2016), 
(Liu et al., 2017). 
Another possible regulatory role of TSPO is suggested for the cardio system. Studies 
showed a critical regulatory role of the physiological cardiac function by TSPO to 
protect the heart under pathological conditions. TSPO might further represent an 
alternative strategy to develop new pharmacological agents to protect the 
myocardium against ischemia–reperfusion injury (Morina et al., 2016). Also, Motloch 
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et al. discussed the role of TSPO in arrhythmogenesis in regard to acute ischemia-
reperfusion injury and myocardial infarction. The recent observations of TSPO as a 
regulator of mitochondrial energy metabolism pathways might enlarge its use from a 
diagnostic inflammatory marker to a therapeutic target of multiple cardiovascular 
disorders, including ischemic heart disease (Motloch et al., 2015). 
The current discussion of TSPO involves various mitochondrial pathways. The new 
insights in recent years changed the scientific landscape of TSPO and opened a new 
way for diagnostic and therapeutic investigations with the primary focus on 
mitochondrial metabolism and protection. 
2.5 TSPO in the brain  
Despite experiments connecting TSPO function to the possible regulation of 
mitochondrial metabolism, the best described process in which TSPO is dynamically 
regulated is the activation of resident microglia in response to brain injury or neuro-
inflammation (Rupprecht et al., 2010), (Albrecht et al., 2016). Only a few cell types in 
the CNS express TSPO under physiological conditions. TSPO is mainly found in glial 
cells (Casellas et al., 2002), reactive astrocytes (Maeda et al., 2007), and in neurons 
(Chen & Guilarte, 2008). TSPO in the brain is highly upregulated in regions of injury 
and inflammation. The observed higher expression of TSPO in injured brain regions 
is defining TSPO as a good marker for neuropathological processes (Setiawan et al., 
2015a,b), (Albrecht et al., 2016). The high affinity and selective ligand PK11195 can 
be labeled with various radio isotopes and is therefore a detecting ligand. Using 
imaging techniques, labeled PK11195 makes injured areas visible. Available 
techniques are the positron emission tomography (PET) and the single photon 
emission computed tomography (SPECT) (Chen & Guilarte, 2008). Under 
neuropathological conditions such as stroke or neurodegenerative disorders, e.g. 
Alzheimer’s disease (Edison et al., 2008), Parkinson’s disease (Ghadery et al., 
2017), Huntington’s disease (Chen & Guilarte, 2008), Multiple sclerosis (Rissanen et 
al., 2014) and amyotrophic lateral sclerosis (Zürcher et al., 2015), TSPO expression 
is increased in reactive microglia and astrocytes (Maeda et al., 2007).  
Furthermore, an antidepressive (Qui et al., 2016), (Zhang et al., 2017), (Li et al., 
2016a), (Li et al., 2016b) and an axiolytic (Schüle et al., 2014), (Nothdurfter et al., 
2012) effect of TSPO is assumed, according to recent in vivo and in vitro studies. 
TSPO is also located in neuronal cells of the spinal cord as well. In comparison to 
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placebo treated animals, a neuropathic pain model in rats showed that progesterone 
administration improved the recovery from neuropathic pain and modulated the 
TSPO expression in the spinal cord. These data suggest that steroid hormones 
probably modulate TSPO levels in the brain (Liu et al., 2014b).  Another finding 
showed that estradiol activates TSPO expression in hypothalamic astrocytes due to a 
calcium-mediated pathway, resulting in enhanced progesterone synthesis (Chen et 
al., 2014). 
 
  
 Aim of the Thesis           23 
3   Aim of the Thesis  
The fundamental basis of this thesis was the development of a reliable and 
reproducible method to characterize the TSPO function in neurosteroid synthesis and 
mitochondrial metabolism. The requirement for the needed method was to facilitate a 
variety of experiments and thereby excluding non-specific side effects. Previous 
TSPO observations, only obtained by the use of TSPO ligands, led to the assumption 
that ligand-induced pharmacological effects could be non-specific or unrelated to 
TSPO. Therefore, I decided to design a TSPO-knock-down in mouse microglia cells 
(BV-2 cells) by means of small interfering RNA (siRNA). This TSPO-gene-silencing 
model gives me the opportunity to perform experiments in presence and absence of 
TSPO.  
Since the recent in vivo and in vitro studies using TSPO knock-out models refuted the 
role of TSPO in steroidogenesis, there is still an open question of the involvement of 
TSPO in neurosteroidogenesis. Therefore, a possible role for TSPO in neurosteroid 
synthesis has to be analyzed in a comparative experiment by means of the 
TSPOknock-down model and Scramble cells. Levels of pregnenolone, the precursor 
molecule of neurosteroids have to be analyzed in TSPO-knock-out-cells and after 
drug-treatment by means of two different techniques: ELISA (enzyme-linked 
immunosorbent assay) and GC/MS (gas chromatography / mass spectroscopy) 
technique.  
Furthermore, the precise physiological and pathological function of TSPO in 
mitochondrial metabolism is still unknown, but there is evidence for a role of TSPO in 
calcium homoeostasis (Gatliff & Campanella, 2012), mitochondrial respiration (Banati 
et al., 2014), glucose homoeostasis (Tu et al., 2016) and other bioenergetic 
parameters reflecting mitochondrial health (Gatliff et al., 2014), (Gatliff & Campanella, 
2016). Therefore, the role of TSPO in mitochondrial metabolism has to be analyzed 
in BV-2scramble and BV-2-TSPOknock-down brain cells to investigate metabolic changes 
with regard to calcium homoeostasis, respiration and mitochondrial membrane 
potential. This observation might help to characterize the role of TSPO in this new 
field of mitochondrial metabolism and gives a deeper insight in the precise function. 
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4 Materials and Methods 
4.1 Cell culture procedure of BV-2 mouse microglia cells 
BV-2 mouse microglia cells were a generous gift from Dr. Marcus Karlstetter (Center 
of Ophthalmology, Experimental Immunology of the Eye, University of Cologne, 
Germany). BV-2 cells were cultured in Roswell Park Memorial Institute Medium 
(RPMI 1640 Medium, PAA Laboratories, Cölbe, Germany) supplemented with 10% 
fetal calf serum (FCS), 1% L-glutamine, 1% (v/v) penicillin-streptomycin and 195 nM 
mercaptoethanol. Cells were cultured at 37 °C, 95% humidity and 5% CO2. 
4.2 TSPO knock-down in BV-2 mouse microglia cells 
Design of mouse TSPO shRNA  
 
The design of the mouse TSPO shRNA (mshTSPO) was taken from RNAi 
Consortioum (Cambridge, UK) for the Gene translocator protein (TSPO) and the 
Taxon Mus musculus (mouse) with the accession number (NM_009775.2). For the 
given target sequence, the following hairpin sequence was used: 
 
Target sequence:  CCGTGCTCAACTACTATGTAT 
Hairpin sequence:  5’-CCGG-CCGTGCTCAACTACTATGTAT-CTCGAG-
ATACATAGTAGTTGAGCACGG-TTTTTG-3’ 
 
Forward and reverse oligos for mshRNA were established and finally produced by 
GENEART AG (Regensburg, Germany): 
 
mshTSPO-F: 5'-CCGGCCGTGCTCAACTACTATGTATCTCGAGATACATAGT 
AGTTGAGCACGGTTTTTG-3' 
mshTSPO-R: 5'-AATTCAAAAACCGTGCTCAACTACTATGTATCTCGAGATA 
CATAGTAGTTGAGCACGG-3' 
 
These oligos contain the shRNA sequence flanked by sequences that are compatible 
with the sticky ends of EcoRI and AgeI. The mshTSPO-F and the mshTSPO-R oligos 
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were annealed and ligated into the pLKO.1 TRC vector (Addgene, Cambridge, USA), 
producing a final plasmid, expressing the shRNA for mouse TSPO. 
 
Cloning of mshTSPO into the pLKO.1 cloning vector 
 
The pLKO.1-TRC cloning vector contains a 1.9 kb stuffer which was digested with 
EcoRI and AgeI restriction enzymes. Following the Addgene protocol (Addgene, 
2006), the mshTSPO-F and mshTSPO-R oligos were resuspended with 
demineralized and distilled water (ddH20) to a concentration of 20 μM. 5 µl of each 
oligo was mixed with 5 μL 10 x NEB buffer 2 (New England Biolabs, Frankfurt a.M., 
Germany) and 20 µl ddH20. This mixture was incubated for 4 minutes at 90 °C, and 
then subsequently cooled down in a 70 °C water beaker to allow the oligos gently 
annealing. 
 
Digesting the pLKO.1 TRC cloning vector 
 
During annealing, the pLKO.1 TRC cloning vector was digested, to integrate the 
construct. According to the protocol (Addgene, 2006), 6 μg of the maxipreparation 
DNA product of pLKO.1 TRC-cloning vector has to be mixed with 5 μL 10x NEB 
buffer, 1 μL AgeI enzyme (New England Biolabs, Frankfurt a.M., Germany) to 50 μL 
ddH20 and incubated for 2 hours at 37 °C. After purification with Qiaquick gel 
extraction kit (QUIAGEN, Hilden, Germany), the extract, diluted in 30 μL of ddH2O, 
was mixed with 5 μL 10x NEB buffer 1 and 1 μL EcoRI and 14 μL ddH2O and was 
finally incubated at 37 °C for 2 hours. A control Gel (0.8% agarose gel) showed two 
bands, one 7 kb and one 1.9 kb. The 7 kb band is the linearized vector and has to be 
cut out, purified with a Qiaquick gel extraction kit and finally eluted in 30 μL of ddH2O. 
 
Ligation and Transformation of mshTSPO into bacteria 
 
For ligation, a standard T4 ligation was used. Therefore, 2 μL of the annealed oligos 
were mixed with 2 µl (20 ng) of the digested pLKO.1 TRC-cloning vector, 2 μL of 10x 
NEB T4 DNA ligase buffer (New England Biolabs) and 1 μL NEB T4 DNA ligase 
(New England Biolabs, Germantown, USA) to 20 μL ddH2O and incubated at 14 °C 
for 20 hours. 2 µl of this ligation mix was transformed into 20 µl of competent DH5α 
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cells (Thermo Fischer Scientific, Darmstadt, Germany) following manufacturer’s 
protocol. The mixture was placed on LB agar plates, containing 100 μg/ml ampicillin 
and incubated at 37 °C overnight. Once positive clones were by blue-white selection, 
the insert of these clones was verified by a sequencing reaction. Finally, one clone 
with proper sequence was selected and a maxipreparation with QIAGEN Plasmid Kit 
was performed, getting a mshTSPO plasmid with a concentration of 1 µg/µl. 
Producing lentiviral particles of the mshTSPO plasmid 
On the first day, 1x106 HEK-293T cells were seeded in one well of a 6 well plate and 
incubated at 37 °C, 5% CO2 overnight. HEK-293T cells were cultured in DMEM + 
10% FBS with penicillin/streptomycin. On the second day, a transfection mix was 
prepared using the calcium-phosphate precipitation. During this process, the desired 
plasmid was bound to precipitated calcium phosphate and the newly formed complex 
can be taken up by the cells. HEK cells that were split the day before on a 6 well 
plate were first treated with chloroquine. Per single well of HEK293T cells, 2 µl 
chloroquine diphosphate stock solution (25 mM in H2O) was diluted 1:1000 in HEK 
media and given to the cells, which were then incubated for 1 hour at 37° C. 
Meanwhile, the transfection mix was assembled in 1.5 ml Eppendorf tubes (table 1). 
After incubation, the chloroquine containing media was replaced by normal HEK 
media and 100 µl of transfection mix was added to each well. To produce infectious 
lentiviruses containing the shRNA against mouse TSPO, HEK cells were left 
undisturbed, incubating at 37 °C, 95% humidity and 5% CO2 for 2 days in the S2 lab. 
 
Substance Amount used for 1 well of HEK cells 
mshTSPO plasmid 3 µg 
psPAX2 plasmid 2.2 µg 
pMD2.G plasmid 0.8 µg 
CaCl2 (2 M) 5 µl 
2 x HBS 50 µl 
ddH2O 39 µl 
 
Table 1 Transfection mix per well of HEK cells. psPAX2 plasmid (Addgene, Cambridge, USA) is 
a second-generation lentiviral packaging vector. pMD2.G (Addgene, Cambridge, USA), is an 
envelope plasmid. 
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Producing lentiviral particles of scramble shRNA plasmid  
On the first day, 1x106 HEK-293T cells were seeded in one well of a 6 well plate and 
incubated at 37 °C, 5% CO2 overnight. HEK-293T cells were cultured in DMEM + 
10% FBS with penicillin/streptomycin. On the second day, a transfection mix was 
prepared using the calcium-phosphate precipitation. During this process, the desired 
plasmid was bound to precipitated calcium phosphate and the newly formed complex 
can be taken up by the cells. HEK cells that were split the day before on a 6 well 
plate were first treated with chloroquine. Per single well of HEK293T cells, 2 µl 
chloroquine diphosphate stock solution (25 mM in H2O) was diluted 1:1000 in HEK 
media and given to the cells, which were then incubated for 1 hour at 37° C. 
Meanwhile, the transfection mix was assembled in 1.5 ml Eppendorf tubes (table 2). 
After incubation, the chloroquine containing media was replaced by normal HEK 
media and 100 µl of transfection mix was added to each well. To produce infectious 
lentiviruses containing the scramble shRNA plasmid, HEK cells were left undisturbed, 
incubating at 37 °C, 95% humidity and 5% CO2 for 2 days in the S2 lab. 
 
Substance Amount used for 1 well of HEK cells 
Scramble shRNA plasmid 3 µg 
psPAX2 plasmid 2.2 µg 
pMD2.G plasmid 0.8 µg 
CaCl2 (2 M) 5 µl 
2 x HBS 50 µl 
ddH2O 39 µl 
 
Table 2 Transfection mix per well of HEK cells. Scramble shRNA plasmid (Addgene, #1864) is a 
3rd gen lentiviral negative control vector containing scrambled shRNA; psPAX2 plasmid 
(Addgene) is a second-generation lentiviral packaging vector. pMD2.G (Addgene, Cambridge, 
USA), is an envelope plasmid. 
Transduction of the plasmids in BV-2 mouse microglia cells 
The incorporation of foreign DNA into another cell by dint of a viral vector is called 
transduction. To transduce the BV-2 cells, the supernatant of the HEK cells that were 
transfected 2 days before with either mshTSPO or scramble plasmid were used, 
since it contained the infectious lentiviruses. In the S2 lab, the virus containing media 
was taken off the HEK cells and sterile filtered through a 40 µm filter to remove any 
remaining virus producing HEK cells, so that only the viral particles themselves were 
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left in the both flow-throughs. The filtered media were put on 90% confluent BV-2 
cells (seeded one day before). To help the BV-2 cells taking up the lentivirus, they 
were centrifuged for 60 min with 2400 RPM at RT. Afterwards, the virus containing 
media was substituted with BV-2 media. During the following days, media of the cells 
was changed daily, including 2 µg/ml puromycin for selection. After five days cells 
were split into petri dishes and after another 5 days they were transferred to the S1 
lab and termed BV-2-TSPOknock-down cells and BV-2scramble cells. 
4.3 Immunohistochemistry 
BV-2scramble cells or BV-2-TSPOknock-down cells were grown for 24 hours on a sterile 
glass coverslip with 12 mm diameter. Then, cells were washed 3 times with 1 × PBS 
(Sigma Aldrich, Munich, Germany) and fixed for 10 minutes at room temperature with 
4% (wt/vol) paraformaldehyde (Carl Roth GmbH, Karlsruhe, Germany). After three 
additional washing steps with PBS, cells were permeabilized with 
blocking/permeabilization solution (10% (vol/vol) normal goat serum and 0.5% 
(vol/vol) Triton X-100 in 1 × PBS) for 20 minutes. Cells were then labeled overnight, 
at 8 °C with rabbit-anti-TSPO antibody (ab109497, Abcam, Cambridge, UK) and 
mouse-anti-ATPB antibody (ab14730, Abcam) both diluted 1:1000 in 2% normal goat 
serum and 0.1% Triton X-100 in 1 × PBS. The next day, after three additional 
washing steps with 1 x PBS, cells were incubated for 1 hour with a secondary 
antibody mixture of CY3 goat-anti-mouse IGG (red) (Life Technologies, Carlsbad, 
USA) and Alexa Fluor 488 goat-anti-rabbit IGG (green) (Life Technologies) both 
diluted 1:1000 in 2% normal goat serum and 0.1% Triton X-100 in 1×PBS. During the 
last 15 minutes of the secondary antibody incubation, DAPI antibody was added in 
1:1000 concentration to the antibody mixture. Finally, cells were mounted with Roti®-
Mount FluorCare (Carl Roth GmbH) and analyzed using an inverted microscope 
(Observer.Z1, Zeiss, Jena) equipped with four different objectives (20x, 40x, 63x, 
100x). The light source was the high-speed wavelength switch Lambda DG4 (XBO 
175 W) from Sutter instruments. Images were taken by a Zeiss AxioCam MRm. 
Every experiment was conducted using the software ZEN (blue edition, 2012) by 
Zeiss. 
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4.4 TSPO distribution in different mouse tissues 
Western blot analysis was performed on fresh whole cell lysates of 9 various organs 
from adult wild-type mice. The densitometrically achieved results of TSPO protein 
expression in these 9 tissue samples were evaluated in relative units (rU) and in 
relation to β-actin as a loading control. Three measurements, each with fresh tissue, 
were performed in double determination.  
4.5 Western Blotting 
Cell preparation 
To prepare the cell lysates of BV-2scramble cells, 5x10
5 cells were seeded in each well 
of a 6 well plate. In an additional approach, to prepare BV-2-TSPOknock-down cell 
lysates, cells were seeded in each well of another 6 well plate. The cells were 
incubated for 4 hours at 37 °C, 95% humidity and 5% CO2. Then, substances in table 
3 were administered to BV-2scramble cells. Additionally, in the solvent control wells of 
BV-2scramble and BV-2-TSPOknock-down cells, as well as in the LPS injected well, 2 µl of 
ethanol were applied to allow equal conditions. Cells were then incubated 24 hours at 
37 °C, 95% humidity and 5% CO2. Media was removed and cells were washed 3 
times with 1 x PBS. 100 µl homogenization buffer (20 mM HEPES, 5 mM EDTA, 1 M 
NaCl) including fresh Protease Inhibitor Cocktail (Sigma Aldrich) was added and cells 
were scrapped.  
 
Stimulant 
Molecular 
weight 
Solvent 
Working 
concentration. 
Incubation 
time 
Company 
XBD173 401.50 g/mol ethanol 10 µM 24 h  APAC, Col., USA 
PK11195 352.86 g/mol ethanol 100 nM 24 h  Sigma 
Ro5-4864 319.19 g/mol ethanol 100 nM 24 h  Sigma 
LPS 1 mg/ml media 100 ng/ml 24 h  Sigma 
 
Table 3  Substances used for Western Blot. All substances which were used for cell incubation 
are listed in this table. Additional information is their molecular weight in g/mol, the used 
solvent, the final working concentration, and the contributors.  
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After scrapped cells were mechanically homogenized on ice, an additional 
homogenization step was needed. Cell lysates were treated with an ultrasonic probe 
(GM 3100 HF, ZEFA, Grasbrunn, Germany) for 30 seconds on ice with 40% power. 
Protein quantification via Bradford assay 
Cell lysates were quantified for their protein concentration by Bradford method 
(Bradford, 1976) with the Bio-Rad Protein Assay Dye Reagent Concentrate (Bio-Rad 
Laboratories, Munich, Germany).  
SDS-PAGE procedure 
After quantification, 20 µg of protein lysates were separated by sodium dodecyl 
sulfate gel electrophoresis (SDS-PAGE) with 15% polyacrylamide gels and were then 
transferred onto a nitrocellulose membrane. Membranes were blocked with 5% non-
fat dry milk in TBST (10 mM TRIS, 150 mM NaCl, 0.1% Tween 20; pH 7.4). The 
membranes were incubated overnight at 4 °C with a rabbit-anti-TSPO antibody 
(ab109497, Abcam) and β-actin with a rabbit-anti-β-actin antibody (Sigma-Aldrich), 
both diluted 1:1000 in 5% non-fat dry milk in TBST. Blots were washed three times 
with TBST and incubated with secondary horseradish peroxidase (HRP)-conjugated 
antibodies goat-anti-rabbit IGG-HRP (Santa Cruz) and donkey-anti-goat IGG-HRP 
(Santa Cruz), both diluted 1:5000 in 5% non-fat dry milk in TBST. Bands were 
detected with the Chemiluminescence Substrate Super Signal West Pico (Fisher 
Scientific, Schwerte, Germany) and visualized with a digital imaging system (Image 
Quant LAS 4000, GE Healthcare Europe). Densitometry analysis was performed with 
Image J Software (Wayne Rasband, National Institute of Health, USA). TSPO values 
were normalized to β-actin. 
4.6 Pregnenolone Quantification 
TSPO might play an important role in cholesterol transport and conversion to 
pregnenolone, the precursor molecule of the neurosteroid synthesis. Therefore, 
pregnenolone was quantified in both BV-2scramble cells and in BV-2-TSPOknock-down 
cells using two different experimental methods. 
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Cell preparation 
1x106 BV-2scramble cells or BV-2-TSPOknock-down cells were seeded each onto petri 
dishes and were incubated four hours at 37 °C, 95% humidity and 5% CO2. Cells 
were treated for 16 hours with substances indicated in table 4. Additionally, in the 
solvent control wells of BV-2scrambleand BV-2-TSPOknock-down cells, as well as in the 
LPS injected well, 10 µl of ethanol were applied to allow equal conditions. Cells were 
then incubated at 37 °C, 95% humidity and 5% CO2. After this first period of 
incubation, plates were washed once with 1 x PBS, and then filled with 10 ml 
pregnenolone assay buffer (140 mM NaCl, 5 mM KCl, 1.8 mM CaCl2, 1 mM MgSO4, 
10 mM glucose and 10 mM HEPES), and 25 µM trilostane (Sigma Aldrich). Trilostane 
was added to inhibit the further metabolism of pregnenolone to neurosteroids. Cells 
were treated again with the compounds according to table 4 for further 8 hours.  
Afterwards, supernatants were stored at -20 °C for further use.  
 
Stimulant Molecular 
weight 
Solvent Working 
concentr. 
Incubation 
time 
Company 
XBD173 401.50 g/mol Ethanol 10 µM 24 h  APAC, USA 
PK11195 352.86 g/mol Ethanol 100 nM 24 h  Sigma 
Ro5-4864 319.19 g/mol Ethanol 100 nM 24 h  Sigma 
LPS 1 mg/ml Media 100 ng/ml 24 h  Sigma 
 
Table 4 Substances used for pregnenolone quantification. Substances used for cell incubation 
are listed in this table. Additionally, the molecular weight in g/mol, the used solvent, the final 
working concentration and the contributors were given.  
 
Two methods were used to quantify pregnenolone concentration, an antibody-based 
measurement method (ELISA) and a gas chromatography/mass spectrometry 
method (GC/MS). In contrast to the ELISA assay, the GC/MS analysis is 20 times 
cheaper and more reliable. This method allows the quantification of three or more 
substances out of one sample in a range from 10 ng/ml up to a dimension of 
gram/milliliter. As the ELISA is more expensive, measurement of just one substance 
out of one sample was possible and quantification was limited up to a maximal 
pregnenolone concentration of 25 ng/ml. An advantage of the ELISA technique was 
its higher sensitivity. The ELISA technique allows pregnenolone quantification 
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starting from 1 ng/ml, whereas GC/MS analysis allows steroid quantification starting 
from 5 ng/ml. 
4.6.1 Enzyme-Linked Immunosorbent Assay (ELISA)  
Supernatants of the cells were used and quantified in an enzyme-linked 
immunosorbent assay (ELISA) for pregnenolone quantification, according to the 
manufacturer’s recommendations (Pregnenolone ELISA, IBL International, Hamburg, 
Germany). 10 µl of each sample was taken and diluted by 40 µl pregnenolone buffer, 
to get the required 50 µl of sample template. These 50 µl were pipetted on a rabbit-
anti-pregnenolone antibody coated 96-microwell plate. 100 µl of pregnenolone-HRP 
conjugate was then added. Ready-to-use-calibrators were provided by IBL 
International. Afterwards 150 µl of tetramethylbenzidine/hydrogen peroxide (TMB) 
substrate was added. After 15 min, 50 µl of stopping solution was pipetted into each 
well. Assays were read with a Tecan Spectraphotometer (Tecan, Crailsheim, 
Germany) at 450 nm. Data were analyzed by Magellan Data Analysis Software 
(Tecan, Version 2.0).  
4.6.2 GC/MS analysis  
SPE extraction  
The internal standard, deuterium labeled pregnenolone-d4 (80 ng) (#Q5500-024, 
Steraloids, Newport, USA) was added to the sample (1 ml of BV-2scramble cells). The 
mixture was then loaded onto the C18 encapped SPE column (3 ml/500 g, Machery-
Nagel, Düren, Germany), previously preconditioned with 3 ml of methanol and 3 ml a 
95%/5% water-methanol, successively. After rinsing the samples with the internal 
standard, the column was washed with 3 ml of the 95%/5% water-methanol mixture. 
The cartridges were dried for ten minutes under vacuum, and then the steroids were 
extracted with 3 ml of methanol. The extract was then evaporated to dryness under a 
nitrogen stream (42 °C). The dry residue was dissolved in 100 µl of ethyl acetate and 
vortexed.  
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Derivatization  
The ethyl acetate extract was derivatized by addition of 20 µl heptafluorobutyric acid 
anhydride reagent (HFBA, Machery Nagel, Düren, Germany) for 30 minutes. After 
derivatization at room temperature, the extract was evaporated to dryness under a 
nitrogen stream (42 °C). The dry residue was then adjusted to 25 μl with toluene and 
decanted in special GC vials. 
Gas chromatography/mass spectrometry (GC/MS) analysis  
Analyses were performed on an HP 6890+ gas chromatograph (Agilent 
Technologies, Palo Alto, CA, USA) fitted with a 5%diphenyl-95%dimethylpolysiloxane 
Optima 5 MS capillary column (25 m × 0.20 mm × 0.20 μm; Machery Nagel, Düren, 
Germany). Samples were injected (3 μl) into the GC in split less (25 psi; 1 min) mode 
at 250 °C using an HP 6890+ series injector. The carrier gas was ultrapure helium 
set at constant flow mode (1.3 ml/min). The reaction gas was methane. The GC 
temperature program was 90 °C (1 min hold) increased to 290 °C (5 min hold) at a 
rate of 7.5 °C/min. The gas chromatograph was coupled to an HP 5973 Mass 
Selective Detector (MSD, Agilent Technologies), operated in negative chemical 
ionization (NCI) mode at 2024 V under the single ion monitoring mode (SIM) using 
the molecular ion of each compound or a specific ion fragment scan/s. The initial 
temperature of the oven was 95°C (1min), followed by a multiple-ramp temperature 
program: 210°C in 30°C/min steps; hold for 3 min -> 235°C in 2.5°C/min steps; hold 
for 9 min -> 300°C in 25°C/min steps; hold for 6 min.  
 
 
Table 5 Quantification and Confirmation Ions (m/z) of the used steroids and the internal 
standard. Pregnenolone-D4* purchased from Steraloids, Newport, USA.  
 
Compound Abbreviation Quatification 
Ion (m/z) 
Confirmation 
Ion (m/z) 
Retention time 
Pregnenolone* Preg 472.4 492.4 27.7 min 
Allopregnenolone* AlloPreg 474.4 494.4 23.9 min 
Tetrahydrodeoxy- 
corticosterone* 
THDOC 515.2 490.4 28.7 min 
Pregnenolone-D4*  476.4 496.4 27.6 min 
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The steroids were quantified in relation to the deuterated steroid pregnenolone-d4, 
used as internal standard. The ions used for quantification (QI, mainly molecular 
ions) and confirmation (Ci) are listed in table 5. The response factors of the different 
compounds were measured by injecting a solution of unlabeled standards mixed with 
deuterated compounds used as internal and syringe standards. No compounds have 
been found in blank samples.  
4.7 The relationship of TSPO ligand pharmacology and neurosteroidogenesis 
The pharmacological profile of three well established TSPO ligands XBD173, 
etifoxine and diazepam with regard to TSPO binding affinity, TSPO expression and 
neurosteroidogenesis was analyzed to figure out any relationship. 
4.7.1 Western Blot 
BV-2wild-type cells were seeded onto 6-well culture plates until 80% confluence. Cells 
were treated for 24 h with XBD173, etifoxine or diazepam at concentrations of 0.1 
µM, 1 µM, 3 µM and 10 µM. These concentrations were chosen according to 
concentrations reached in the cerebrospinal fluid of humans treated with diazepam 
(Kanto et al., 1975). Solvent (ethanol) concentration was 0.5% in each well.  
Protein quantification via Bradford assay and SDS-PAGE procedure was performed 
according to the protocol in 4.5. TSPO values were normalized to β-actin as a 
loading control. 
4.7.2 Pregnenolone ELISA  
BV-2wild-type cells were seeded onto 24-well plates. 80% confluent cells were treated 
for 24 h with etifoxine, XBD173 or diazepam directly added to the medium at 
concentrations of 0.1 µM, 1 µM, 3 µM and 10 µM, respectively.  
The ELISA assay procedure was performed according to the protocol in 4.6.1. 
Pregnenolone concentrations were normalized to solvent control.  
4.7.3 [³H]PK11195 radioligand binding assay 
[3H]PK11195 saturation binding assays were performed using cell lysates of BV-2wild-
type cells, prepared as previously described. Lysates were homogenized with assay 
buffer (50 mmol/l TRIS; pH = 7.4) and pipetted into a 96-well plate at a final volume 
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of 100 µl containing 35 μg total protein per well. Saturation binding assays included 
the following concentrations: 0.1 nM, 0.5 nM, 1 nM, 2 nM, 3 nM, 4 nM, 5 nM and 6 
nM of [3H]PK11195 (Perkin Elmer, Downers Grove, IL, USA) with a specific activity of 
82–83 Ci/mmol. Samples were incubated with 10 μmol/l unlabeled PK11195 (Sigma-
Aldrich). Competitions were performed with [3H]PK11195 at a concentration of 1 nM 
for each sample. The competitors etifoxine, XBD173 or diazepam were added at 
concentrations of 0.1 nM, 0.5 nM, 1 nM, 5 nM, 10 nM, 15 nM and 20 nM, 
respectively. The concentrations of competing compounds were chosen according to 
the Kd value of [
3H]PK11195, which had a high binding affinity already at nanomolar 
concentrations (data not shown). Assays were incubated at 25°C for 60 min and then 
terminated by vacuum filtration through a UniFilter-96 GF/C with 1.2 µm pore size 
(PerkinElmer) with ice-cold assay buffer. The amount of bound [3H]PK11195 was 
determined using a Mikroszint 20 (Perkin Elmer) and the Tri-Carb 2900TR Liquid 
Scintillation Analyzer (Perkin Elmer). Data (disintegration per minute) were 
transformed to fmol [3H]PK11195 bound per mg protein (fmol/mg). Specific binding 
values were calculated and saturation binding data were analyzed by nonlinear 
regression with GraphPad Prism 5.0 (San Diego, CA, USA). Bmax and KD values, 
respective measures of [3H]PK11195 binding capacity (indicating PBR/TSPO 
density), were also measured with Graph Prism 5.0. 
4.8 Analysis of intracellular Ca2+ levels with FURA-2 dye 
Imaging setup and application system 
A Zeiss inverted microscope (Observer.Z1) equipped with four different objectives 
(20x, 40x, 63x, 100x; see supplements) was used (figure 2). As light source the high-
speed wavelength switch Lambda DG4 (XBO 175 W; Sutter instruments, Novato, 
USA) was used, and images were taken with AxioCam (MRm; Carl Zeiss 
Microscopy) with a special filter for FURA-2, explained in the next paragraph. Every 
experiment was conducted using the software ZEN (Blue Edition, 2012; Carl Zeiss 
Microscopy). The custom-made perfusion system consists of ten 10 ml glass 
syringes connected to an adjustable pressure source via plastic tubes. The glass 
syringes were filled with ringer solution and substances, used for stimulation, 
explained and listed later. From each syringe, a single small-diameter plastic tube 
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leads to the mixing chamber, where the different channels meet to form the inflow. 
The tubes can be individually opened and closed by dint of electromagnetic pinch 
valves, controlled via the associated panel. The inflow is then placed in the bathing 
chamber and provides constant application of the experimental solutions. A suction 
device is placed at the other end of the chamber to circumvent overflow. 
 
 
 
Figure 2 Calcium Imaging Setup.  
The calcium imaging setup consists of a Zeiss inverted microscope (Observer.Z1) with four different 
objectives (20x, 40x, 63x, 100x). The light source is the high-speed wavelength switch Lambda DG4 (XBO 
175 W, Sutter instruments). Images are taken by a AxioCam MRm (Zeiss). On the right is the application 
system and the control panel.  
 
FURA-2-AM fluorescence dye and stimulants used within the calcium imaging setting 
FURA-2-acetoxymethyl ester (FURA-2-AM; Invitrogen/Life technologies, Karlsruhe, 
Germany) is a membrane permeable aminopolycarboxylic acid with a molar mass of 
636.50 g/mol. FURA-2-AM is widely used as a fluorescent, ratiometric dye for the 
quantitative measurement of free cytosolic Ca2+ concentrations in living cells (Tsien et 
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al., 1985). FURA-2-AM crosses the cell membrane and once inside the cell, the 
acetoxymethyl groups are removed by cellular esterases. Removal of these esters 
regenerates "FURA-2", the pentacarboxylate calcium indicator and a Ca2+ chelating 
agent. FURA-2 in non-bound state has maximal absorbance at 363 nm, which shifts 
to 335 nm when Ca2+ is available and bound to FURA-2. Excitation with both 
wavelengths leads to emission of light at around 510 nm (512 nm as free molecule, 
505 nm as complex with Ca2+). It is a great advantage to use FURA-2 as a 
ratiometric dye. Confounding factors such as cell thickness or loading concentrations 
are annulled automatically (Tsien et al., 1985).  All substances for stimulation, used 
within the Ca2+ imaging setting to investigate the involvement of TSPO in Ca2+ 
signaling, are listed in table 6. 
Cell preparation  
2x105 BV-2scramble cells and BV-2-TSPOknock-down cells were seeded each on ø 25 mm 
sterile glass coverslips, placed in 6 well plates, and incubated over night at 37 °C, 
95% humidity and 5% CO2. Then, cells were incubated with the substances of table 6 
by pipetting into cell media to achieve the final working concentration. Additionally, to 
achieve comparable experiments, 2 µl ethanol was pipetted in the media for the 
control of BV-2scramble and BV-2-TSPOknock-down cells and in the LPS well. Then, cells 
were incubated 24 h at 37 °C, 95% humidity and 5% CO2. 
 
Stimulant Molecular 
Weight 
Solvent Working 
conc. 
Field of 
Application 
Company 
ATP 507.18 g/mol ringer 100 µM acute (perfusion) Roth, GER 
FCCP 254.17 g/mol ethanol 10 µM acute (pipette) Biomol, GER 
XBD173 401.50 g/mol ethanol 10 µM 24 h incubation APAC 
PK11195 352.86 g/mol ethanol 100 nM 24 h incubation Sigma 
Ro5-4864 319.19 g/mol ethanol 100 nM 24 h incubation Sigma 
LPS 1 mg/ml media 100 ng/ml 24 h incubation Sigma 
 
Table  6 Substances used in calcium imaging experiment. All substances used for Ca
2+ 
imaging 
are listed in this table. Additional information is their molecular weight in g/mol, the used 
solvent and the final working concentration, as well as the contributors and the field of 
application. 
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FURA-2 imaging procedure 
After 24 h, cells have been prepared the following way: FURA-2 working solution was 
prepared (2 µl of FURA-2/AM and 2 µl of Pluronic (10% in H2O; Pluronic® F-127, 
Sigma, Seeze, Germany)) Pluronic is a nonionic, surfactant polyol (molecular weight 
approx. 12,500 Da) that has been found to facilitate the solubilization of dyes and 
other materials in physiological media (Malgaroli et al., 1987). This mixture was 
diluted in 1 ml of Opti-MEM® to obtain a final FURA-2 concentration of 2 µM. For cell 
incubation, media of 6 well plates, containing coverslips was substituted by the 
prepared solution and cells were allowed to take up the dye for 30 min at 37 °C, 95% 
humidity and 5% CO2. Afterwards, the coverslip was taken out of the fluid and placed 
into a bath chamber, washed with classic ringer solution, and mounted onto the Zeiss 
inverted microscope, where they were perfused permanently with ringer for at least 2 
minutes before the start of the experiment. 1 ml of the prepared solution is usually 
reused for incubation of cells up to three times. Therefore, 1 ml of Opti-MEM® 
containing FURA-2 was sufficient to conduct up to 3 single measurements. 
After ensuring that no more agglomerated pieces of FURA-2/AM dye were floating in 
the field of view, measuring of intracellular free and bound Ca2+ was carried out. 
Therefore, a high-speed polychromator system, switching the wavelength of 
excitation light between 340 and 380 nm at a 2 s interval, was used. The emitted light 
was filtered with a FT409 nm and BF510/90 nm filter and detected by the attached 
digital camera. Experiments were executed using the 40x objective, exposure times 
of 30 ms, and a binning of 4x4.  
In the beginning of the experiments (a typical experimental pattern is shown in figure 
14) ATP was applied extracellularly by means of the perfusion system for 60 
seconds. Sill vital cells should now show an increase of intracellular Ca2+, because 
ATP stimulates purinergic receptors (P2X and P2Y), which are present in almost all 
mammalian tissues (Abbracchio et al., 2009). P2Y is a Gq protein-coupled receptor, 
activating phospholipase C (PLC), which then cleaves the phospholipid 
phosphatidylinositol-4,5-bisphosphate (PIP2) into diacyl glycerol (DAG) and inositol-
1,4,5-trisphosphate (IP3). DAG remains bound to the membrane, and IP3 is released 
as a soluble molecule into the cytosol. IP3 then binds to IP3 receptors, which are, as 
mentioned above, particular Ca2+ channels in the endoplasmic reticulum (ER). These 
channels are specific to Ca2+ and only allow Ca2+ to move through. After another 
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washing step Ca2+ concentration returned to basal levels and the intracellular Ca2+ 
stores recovered, before the p-trifluoromethoxy-phenylhydrazone (FCCP) application 
was carried out. FCCP is an ionophore and an uncoupling agent, meaning that it 
disrupts the mitochondrial membrane potential and therefore interrupts the 
ATP synthesis (Heytler, 1962). The resulting depolarization of the mitochondrial 
membrane potential and the loss of ATP further lead to an efflux of Ca2+ from 
mitochondrial stores (Duchen, 1990). Due to the fact that FCCP is highly lipid soluble 
and to avoid that it is absorbed by the plastic/silicon tubules of the perfusion system, 
we decided to apply it directly via pipette to the chamber. Therefore, perfusion was 
stopped when cells were slightly covered with ringer solution. The FCCP stock was 
solved in ringer solution to reach a concentration of 10 µM and an ethanol 
concentration less than 1 promille. Finally, 300 µl of the FCCP (10 µM) solution was 
added to the perfusion bath, still in stop-mode, for 60 seconds to provoke any 
reaction. Subsequently washing with ringer solution, until the reaction went back to 
the baseline, was done. 
FURA-2 ratio (Fratio 340/380) images were displayed and the Fratio values from the 
regions of interest (ROIs) drawn on individual cells were monitored during the 
experiments and analyzed later offline with IgorPro (Wavemetrics, Portland, USA). 
4.9  Mitochondrial membrane potential analysis with JC-1 dye 
JC-1 staining technique is used to detect the mitochondrial membrane potential (in 
intact, viable cells (Zamzami et al., 2000). The mitochondrial membrane potential is 
generated by the mitochondrial electron transport chain, which drives a proton flow 
from matrix through inner mitochondrial membrane to cytoplasm, thus creating an 
electrochemical gradient. This gradient is in turn responsible for the formation of ATP 
molecules by the ATP synthase and therefore, the mitochondrial membrane potential 
is an important parameter for mitochondrial functionality and an indirect parameter for 
energy status of the cell.  
Imaging setup and application system 
The imaging setup of JC-1 was used in the same way as above in imaging setup and 
application system of FURA-2 Ca2+imaging (figure 2). A Zeiss inverted microscope 
was equipped with four different objectives, the high-speed wavelength switch 
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Lambda DG4 as light source and the AxioCam MRm for taking images with a special 
filter for JC-1. The experiments were conducted by using the ZEN software.  
JC-1 fluorescence dye and stimulants used within the mitochondrial membrane 
potential measurement setting 
JC-1 (5, 5’, 6, 6’-tetrachloro-1, 1’, 3, 3’-tetraethyl-benzimidazolcarbocyanineiodide; 
Biomol, Hamburg, Germany) is a cationic dye that exhibits potential-dependent 
accumulation in mitochondria, indicated by a fluorescence emission shift from green 
(~ 525 nm) to red (~ 590 nm). On the one hand, a high mitochondrial membrane 
potential in cells leads to the formation of JC-1-aggregates, thus showing red 
fluorescence. On the other hand, cells with a low mitochondrial membrane 
potential are those in which JC-1 maintains in the monomeric form, thus showing 
green fluorescence (Smiley et al., 1991). During JC-1 usage, all reagents must be at 
room temperature and carefully checked for pH (7.4), due to the fact that the 
mitochondrial membrane potential is very sensitive to alterations of both parameters. 
Due to the light sensitivity of JC-1, staining procedure must not be carried out under 
direct light and therefore cells were incubated in the dark. 
Cell preparation  
2x105 BV-2scramble cells and BV-2-TSPOknock-down cells were seeded each on ø 25 mm 
sterile glass coverslips, placed in 6 well plates, and incubated overnight at 37 °C, 
95% humidity and 5% CO2. Then, cells were incubated with the substances listed in 
table 7 by pipetting into cell media to achieve the final working concentration. 
Additionally, to achieve comparable experiments, 2 µl ethanol was pipetted into the 
media for the solvent control and for LPS. Then, cells were incubated 24 h at 37 °C, 
95% humidity and 5% CO2. 
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Stimulant Molecular 
Weight 
Solvent Working 
concentration 
incubation Company 
XBD173 401.50 g/mol ethanol 10 µM 24 h APAC,Columbia, USA 
PK11195 352.86 g/mol ethanol 100 nM 24h Sigma, Seeze, GER 
Ro5-4864 319.19 g/mol ethanol 100 nM 24 h Sigma, Seeze, GER 
LPS 100µg/ml Media 100 ng/ml 24 h Sigma, Seeze, GER 
 
Table 7 Substances used for the mitochondrial membrane potential analysis. All substances 
used for cell stimulation in the JC-1 measurement are listed in this table. Additional 
information is their molecular weight in g/mol, the used solvent and the final working 
concentration, as well as the contributors.  
JC-1 imaging procedure 
After 24 hours, the JC-1 procedure was performed the following way: after freshly 
preparing the JC-1 working solution (1 µl of JC-1 dye plus 1 µl Pluronic; diluted in 100 
µl of Opti-MEM® to obtain a 1:100 pre-dilution), 20 µl of this pre-dilution were mixed 
with 2 ml of Opti-MEM® to achieve a JC-1 working concentration of 2 µM. For cell 
incubation media of 6 well plates containing coverslips was substituted with the 
prepared JC-1 working solution and cells were allowed to take up the dye for 30 min 
at 37 °C, 95% humidity and 5% CO2. Afterwards, the coverslip was taken out of the 
solution and placed into a bath chamber, washed with classic ringer solution, and 
mounted onto the Zeiss inverted microscope, where they were analyzed. Therefore, 
a high-speed polychromator system, switching the wavelength of the excitation light 
between 485 and 590 nm was used. Every two seconds a pair of pictures has been 
taken. The emitted light was filtered with a 515-545 nm filter for the green aggregate 
and 575-625 nm for the red aggregate and finally detected by the attached digital 
camera. Experiments were performed with a 40x objective, an exposure time of 15 
ms, and a binning of 4x4. For a precise detection of the cells regions of interest 
(ROI’s) were selected and the fluorescence was measured within these ROIs. 
4.10 Mitochondrial respiration experiments  
To figure out TSPO’s involvement in the respiratory control, there are many methods 
to analyze mitochondrial function and dysfunction in a system of isolated 
mitochondria, permeabilized cells or even intact cells.  
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4.10.1 Analysis of mitochondrial respiration in intact cells  
The Oxygen consumption rate (OCR) 
The mitochondria in intact cells are present in their physiological environment. They 
are exposed to a relevant mix of substrates and ions. They interact with the 
cytoplasm, plasma membrane and other organelles and cell structures. The oxygen 
consumption rate (OCR) in BV-2scramble cells and BV-2-TSPOknock-down cells were 
determined by using the Seahorse XFp Flux Analyzer (Agilent Technologies, Santa 
Clara, USA). OCR is an indicator of mitochondrial respiration in a special 
experimental layout which informs about respiratory control of the cells (Gerencser et 
al., 2009). Chemical compounds and Seahorse XFp-consumables (Seahorse 
cartridges and Seahorse miniplates) in this experiment were purchased from Agilent 
Technologies. 
The Cell preparation in XFp miniplate and preparation of the XFp sensor cartridge 
7x104 BV-2scramble cells and BV-2-TSPOknock-down cells were seeded each in XFp 8 well 
miniplates and stored for 4 hours at 37 °C, 95% humidity and 5% CO2, allowing the 
cells to attach. Then, cells were incubated with substances, shown in table 8, for 24 h 
at 37 °C, 95% humidity and 5% CO2. 24 hours before the experiment, 200 µl of the 
Seahorse XF Calibrant (pH 7.4) was added to each well of the XFp 8 well utility 
plates and the sensor cartridge was placed on top of the utility plate and hydrated for 
16 h at 37 °C in a non-CO2 incubator. 1 hour before measurement assays were 
initiated by replacing the growth medium from the XFp-miniplates with assay buffer, 
prepared according to the manufactures recommendations.  After three additional 
washing steps cells were incubated again at 37 °C, 95% humidity and 5% CO2 for 60 
minutes to allow temperature and pH of the media to reach equilibrium.  
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Stimulant 
Molecular 
weight 
Stock 
Solvent 
1:100 
Solvent 
Working 
concentr. 
applied 
volume 
Company 
XBD173 401.50 g/mol Ethanol Media 10 µM 2 µl APAC 
PK11195 352.86 g/mol Ethanol Media 100 nM 2 µl Sigma 
Ro5-4864 319.19 g/mol Ethanol Media 100 nM 2 µl Sigma 
DAA-1106 395.42 g/mol Ethanol Media 10 nM 2 µl Clearsyn, Can 
 
Table 8 Substances used in the Seahorse respiration analysis of intact cells. All substances, 
which were used for stimulation in the Seahorse respiration experiment are listed in this table. 
Additional information is their molecular weight in g/mol, the used solvent and the final 
working concentration, as well as the contributors.  
Loading the stimulants of the XFp Cell Mito Stress Kit in the XFp sensor cartridge 
Before running the protocol, the XFp sensor cartridge with the utility plate was 
removed from the non-CO2 incubator. Simultaneously, the mitochondrial stress 
compounds, oligomycin (1 µM), FCCP (2 µM) and rotenone/antimycin (1 µM), 
delivered within the XFp Cell Mito Stress Test Kit were prepared according to the 
manufactures recommendations. Substances were immediately pipetted into the 
respective application ports in the XFp sensor cartridge.  
Analysis of mitochondrial respiration in intact cells 
The XFp sensor cartridge was placed on top of the XFp 8-well miniplate and the 
protocol for basal measurements at 37 °C was started 
(start, calibration, equilibration, mixing 2 min, 1 min delay and 3 min measurement) 
and repeated three times. As illustrated in figure 3 each modulator targets a specific 
component of the ETC.  
Oligomycin inhibits the ATP synthase and thereby the oxygen consumption until 
the LEAK state of respiration is reached. This represents a non-phosphorylating 
resting state when ATP synthase is not active.  
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Figure 3 A classic Seahorse measurement of mitochondrial respiration in intact cells. Basal 
respiration is the O2 consumption of the cells under basal conditions. It is described as the 
sum of O2 consumption from ATP demand and the proton leak. ATP production is the 
difference of basal respiration a resulting proton leak after application of the ATP synthase 
inhibitor oligomycin. H+ (Proton) Leak is the remaining basal O2 consumption, which is not 
coupled to ATP production. It is also a mechanism to regulate the mitochondrial ATP 
production. Maximal respiration is the maximal O2 consumption of the cells as a result of the 
addition of the uncoupler FCCP. FCCP mimics physiological “energy demand” by stimulating 
the respiratory chain to operate at maximum capacity. Therefore, it shows the maximal 
respiration rate of the cell. Spare Respiratory Capacity is the cells ability to respond to 
spontaneous energetic demands. Non-mitochondrial Respiration is the O2 consumption due to 
other cellular enzymes that continue respiring after rotenone and antimycin A addition.  
 
This correlates to the mitochondrial respiration, which is associated with cellular ATP 
production. FCCP as an uncoupling agent collapses the proton gradient and disrupts 
the mitochondrial membrane potential resulting in an unlimited electron flow through 
the ETC whereby O2 is maximally consumed by complex IV. This state of maximal 
respiration can be used to calculate spare respiratory capacity, defined as the 
difference between maximal respiration and basal respiration. Spare respiratory 
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capacity is defined as the cells’ ability to respond to an increased energy demand. 
Finally, a mix of rotenone (complex-I-inhibitor) and antimycin A (complex-III-inhibitor) 
is injected and shuts down the mitochondrial respiration. Thereby it allows the 
calculation of non-mitochondrial respiration driven by processes outside the 
mitochondria (Gerencser et al., 2009). The data for each reported parameter reﬂect 
three independent Seahorse XFp measurement series. 
4.10.2 High resolution respirometry (HRR) with the oxygraph-2k (O2k)  
High-resolution respirometry (HRR) protocols are termed substrate–uncoupler–
inhibitor titration (SUIT) protocols and are available for analysis of mitochondrial 
respiratory control and the pathophysiology of mitochondrial diseases. The aim of the 
experiment was to gain insight into mitochondrial respiration of permeabilized cells 
and which respiratory chain complex might be influenced by a loss of TSPO. This 
was analyzed by comparing BV-2-TSPOknock-down cells to BV-2scramble cells. 
Cell preparation 
1x106 BV-2scramble cells and 1x10
6 BV-2-TSPOknock-down cells were seeded each in 10 
cm petri dishes and stored at 37 °C, 95% humidity and 5% CO2. One petri dish was 
used for one experiment. After two days of regular media change, growth media was 
removed and cells were washed two times with MIR05 media (0.5 mM EGTA, 3 mM 
MgCl2x6H2O, 60 mM lactobionic acid, 20 mM taurine, 10 mM KH2PO4, 20 mM 
HEPES, 110 mM D-sucrose, 1 g/L fatty acid free BSA) (Gnaiger, et al., 2000). Cells 
were harvested in 2 ml of MIR05 media, centrifuged 3 minutes at 1200 RPM and 
resuspended in 1 ml MIR05 media. Cells were counted and the required amount was 
added to the Oxygraph-2k chambers. 
High resolution respirometry procedure 
1x106 cells were transferred into each calibrated Oxygraph-2k (O2k, OROBOROS 
INSTRUMENTS) 2 ml-chambers. BV-2scramble cells were pipetted into chamber A and 
BV-2-TSPOknock-down cells into chamber B. Oxygen polarography was performed at 
37 ± 0.001 °C (electronic peltier regulation) in O2k-chambers and oxygen 
concentration (μM) as well as oxygen flux per tissue mass (pmol O2 x s
− 1 x mg− 1) 
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were recorded in real-time using DatLab software (Oroboros Instruments). In the 
used SUIT protocol, cells were permeabilized by administration of 4 µl digitonin. Non-
phosphorylating LEAK-respiration was induced by adding complex-I-linked substrates 
malate (0.5 mM) and glutamate (10 mM) but no ADP. If no ADP was phosphorylated 
by ATP synthase, the low oxygen consumption during this non-phosphorylating 
LEAK-respiration relates to the proton leak and proton slip. 
A saturating ADP concentration (2.5 mM; previously tested) was then applied to the 
chambers. Complex-I-linked oxidative phosphorylation (OXPHOS) capacity was 
investigated as a result of phosphorylating complex-I-activity. This gives an insight 
into any complex-I-linked alteration in BV-2scramble cells in comparison with BV-2-
TSPOknock-down cells.  
After addition of the complex-II-linked substrate succinate (10 mM), the combined 
complex-I and complex-II-linked OXPHOS-capacity was analyzed. As a 
consequence, with this technique complex-I and complex-II-linked O2 consumption 
was detectable separately. 
Further injection of the ATPase inhibitor oligomycin (2.5 µM) inhibits O2 consumption 
until the LEAK state of respiration is reached, representing again the non-
phosphorylating resting state when ATP synthase is not active.  
In the next step FCCP (2 µM), as an uncoupling agent, was applied and collapses 
the proton gradient, thereby disrupting the mitochondrial membrane potential. As a 
result, electron flow through the ETC is uninhibited and oxygen is maximally 
consumed by complex IV. This condition was used to measure the maximal 
respiratory capacity of the electron transfer system (ETS). The ETS capacity is the 
non-coupled state at optimum uncoupler concentration.  
Subsequent inhibition of complex-I by rotenone (0.5 μM) allowed measurement of 
complex-II-linked ETS capacity. To control whether other oxygen-consuming 
processes are involved in mitochondrial respiration, complex III was inhibited by 
antimycin A (2.5 µM). The resulting residual oxygen consumption (ROX) reflected 
oxygen consumption from undefined sources and was subtracted from mitochondrial 
respiratory states (Gnaiger, 2014). Respiratory fluxes were corrected automatically 
by DatLab for instrumental background according to the manufactures 
recommendations.   
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5 Results 
5.1 Confirmation of the BV-2-TSPOknock-down  
The designed mouse TSPO shRNA (mshTSPO) and the scramble shRNA (lentiviral 
negative control containing scrambled shRNA) were successfully cloned into pLKO.1 
vectors and further stable transfected via lentiviral particles into BV-2 mouse 
microglia cells. The final cells were termed BV-2-TSPOknock-down and BV-2scramble cells. 
To prove the silenced target gene expression via RNA interference, western blot 
analysis of TSPO expression and immunohistological staining against TSPO was 
performed.  
Western Blot analysis of BV-2-TSPOknock-down and BV-2scramble cells 
Western Blot analysis shows a successful 95.5% knock-down in BV-2-TSPOknock-down 
cells, compared to BV-2wild-type and BV-2scramble cells ten days after lentiviral knock- 
  
 
 
Figure 4 TSPO protein expression of BV-2wild-type (WT) cells, BV-2scramble cells (SCR) and BV-2-
TSPOknock-down (KD) cells after 10 days (a-b) and 25 days (c-d) lentiviral knock-down procedure. 
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down procedure (figure 4a-b). Western Blot analysis 25 days after lentiviral knock- 
down showed a significant reduction of TSPO protein expression levels of 88.2 % 
(figure 4 c-d). There was no change in level of TSPO expression in BV-2wild-type and 
BV-2scramble cells after 10 and 25 days. 
Immunofluorescence analysis of BV-2-TSPOknock-down and BV-2scramble cells 
An anti-TSPO antibody staining showing presence of TSPO (green) in the BV-2-
TSPOscramble cells and its absence in the BV-2-TSPOknock-down cells (figure 5a). 
Additional antibody staining of mitochondria (target: mitochondrial membrane ATP 
synthase) (orange; figure 5b) and DAPI staining of nuclei (blue; figure 5c) were used 
in BV-2scramble and BV-2-TSPOknock-down cells for normalization. The merged picture is 
shown in figure 5d. 
 
 
 
Figure 5 The anti-TSPO antibody staining shows the presence of TSPO (green) in BV-2scramble 
cells (SCR) and its absence in BV-2-TSPOknock-down cells (KD) (5a). Additional antibody staining 
of mitochondria (target: ATPsynthase; orange; 5b) and DAPI staining of nuclei (blue; 5c) were 
used in BV-2scramble and BV-2-TSPOknock-down cells for normalization. The merged picture is 
shown in figure 5d. green=TSPO; orange =mitochondria; blue=nuclei; yellow =merged image; 
white scale bar: 10 µm.  
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5.2 Low TSPO expression in mouse wild-type brain 
TSPO is a ubiquitous expressed protein in mammals, but the lowest expression 
levels are detected in the brain. To get an overview of the percentage distribution of 
TSPO in a mouse body western blot analysis was performed on whole cell lysates of 
9 different organs from adult wild-type mice (figure 6b). The TSPO protein expression 
in these 9 tissue samples was presented as arbitrary units (rU) in relation to β-actin 
as a loading control (figure 6a). Three independent experiments were performed. The 
average and the standard error of the mean were calculated and the TSPO protein 
expression is shown in figure 6a. While the highest levels of TSPO were observed in 
lysates from liver (27.4%) and the abdominal visceral fat (18.3%), TSPO protein was 
also detectable at moderate levels in samples from kidney (11.2%), testis (10.4%), 
lung (10.2%) and heart (9.5%). The lowest levels were detected in cerebellum (2.9%) 
and brain lysates (1.6%).  
 
 
 
Figure 6 TSPO protein expression in nine different mouse tissues. (b) Western Blot analysis on 
whole cell lysates from 9 various organs of adult wild-type mice (a). Results were normalized to 
β-actin as a loading control and the data are shown in ratio to loading control (a). n=3; mean 
and standard error of the mean) (Li=liver; VF=visceral fat; KI=kidney; Te=testis; Lu=lung; 
He=heart; Sp=spleen; Ce=cerebellum; Br=brain)  
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5.3 Regulation of TSPO protein expression  
The effect of 24 hour TSPO ligand incubation on TSPO protein expression in BV-
2scramble cells was analyzed by Western blot (figure 7b), to figure out if one of the 
drugs, used in this thesis, is able to influence the TSPO expression and if there is a 
correlation to the resulting TSPO function. 
  
 
 
Figure 7 TSPO protein expression after drug administration and 24 h incubation. Seven 
independent experiments were performed, results are presented as arbitrary units (rU), 
normalized to β-actin and in relation to solvent control. 
 
Seven independent experiments were performed in duplicates on BV-2scramble cell 
lysates after 24 h treatment with XBD173 (10 µM), PK11195 (100 nM), Ro5-4864 
(100 nM) and LPS (100 ng/ml). The average of the duplicates was used to determine 
the average and standard error of the mean. The results were presented as arbitrary 
units (rU), normalized to β-actin (figure 7a) and in relation to solvent control. The 
TSPO expression in percent over solvent control is shown over each column.  
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PK11195 treatment showed the highest, but not significant TSPO protein expression 
with 51%, followed by a significant 47% increase of TSPO protein expression after 
LPS treatment (t-test, p=0.00793). XBD173 and Ro5-4864 showed a moderate 
increase of TSPO expression with 33% and 34%.   
Furthermore, the effect of 24 hour TSPO drug incubation on TSPO protein 
expression in BV-2-TSPOknock-down cells was analyzed by Western blot (figure 8b), to 
investigate if the drug incubation has the same effect on BV-2-TSPOknock-down cells.  
Six independent experiments were performed in duplicates on BV-2-TSPOknock-down 
cell lysates after 24 h treatment with XBD173 (10 µM), PK11195 (100 nM), Ro5-4864 
(100 nM) and LPS (100 ng/ml). The results were presented as the average and the 
standard error of the mean as arbitrary units (rU), normalized to β-actin (figure 8a) 
and in relation to solvent control. 
 
 
 
Figure 8 TSPO protein expression in BV-2-TSPOknock-down cells after drug administration and 24 
h incubation. Six independent experiments were performed, results are presented as arbitrary 
units (rU), normalized to β-actin and in relation to solvent control.  
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XBD173, PK11195, Ro5-4864 and LPS treatment of BV-2-TSPOknock-down cells 
showed a significant decrease in TSPO protein expression when compared to BV-
2scramble solvent control (t-test; p<0.0001; SCR=100%, KDXBD173=16%, 
KDPK11195=12%, KDRo5-4864=18%, KDLPS=15%) (figure 8a). XBD173, PK11195, Ro5-
4864 and LPS treatment of BV-2-TSPOknock-down cells showed no significant 
differences in TSPO protein expression when compared to BV-2-TSPOknock-down cell 
solvent control (KDsolvent control=16%, KDXBD173=16%, KDPK11195=12%, KDRo5-4864=18%, 
KDLPS=15%). Figure 8 shows that TSPO specific drugs do not affect TSPO protein 
expression in BV-2-TSPOknock-down cells. In conclusion, this result clearly confirms the 
TSPO knock-down in BV-2 mouse microglia cells.  
5.4 Pregnenolone quantification with ELISA technique 
TSPO-specific drugs are assumed to develop an anxiolytic effect by their ability to 
enhance or reduce neurosteroid synthesis. Therefore, pregnenolone (precursor 
molecule of all neurosteroids) was quantified after treatment with XBD173 (10 µM), 
PK11195 (100 nM), Ro5-4864 (100 nM) and LPS (100 ng/ml) in cell culture 
supernatants of BV-2scramble cells and BV-2-TSPOknock-down cells by ELISA technique 
(figure 9).  
Four independent experiments were performed in duplicates and normalized to 
solvent control. The average of the duplicates was used to determine the average 
and standard error of the mean shown in figure 9a-c.  
A pregnenolone concentration of 14.30 ng/ml was detected in XBD173 treated BV-
2scramble cells. This significant increase (t-test; p=0.0032) when compared to BV-
2scramble solvent control (7.79 ng/ml) indicates a putative TSPO-specific effect (figure 
9a). All other treatments led in a decrease of pregnenolone concentration when 
compared to BV-2scramble solvent control. This decrease in pregnenolone 
concentration was significant after PK11195 (5.30 ng/ml; t-test: p= 0.0261) and Ro4-
5684 (5.96 ng/ml; t-test: p=0.015) treatment (figure 9a). A non-significant decrease in 
pregnenolone concentration (4.48 ng/ml) was detected in LPS treated cells (figure 
9a). BV-2-TSPOknock-down cells show no significant differences after drug treatment 
when compared to BV-2-TSPOknock-down solvent control (figure 9b).   
BV-2-TSPOknock-down cells showed a significant decrease in pregnenolone 
concentration (4.75 ng/ml; t-test: p=0.0002) when compared to BV-2scramble cells (7.79 
ng/ml), (figure 9c) which demonstrates a functional role for TSPO in  
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Figure 9 Pregnenolone quantification of BV-2scramble cells and BV-2-TSPOknock-down cells with 
ELISA technique after 24h drug incubation. Four independent experiments were performed and 
normalized to solvent control. The average and the standard error of the mean were calculated. 
9a) Pregnenolone quantification of BV-2scramble cells after 24h drug incubation. 9b) 
Pregnenolone quantification of BV-2scramble cells after 24h drug incubation. 9c) The direct 
comparison of 24h treated XBD173, PK11195, Ro5-4864 and LPS BV-2-TSPOknock-down cells with 
BV-2scramble cells.  
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neurosteroidogenesis. The direct comparison of XBD173, PK11195, Ro5-4864 and 
LPS treated BV-2-TSPOknock-down and BV-2scramble cells is shown in figure 9c. A 
significant decrease of pregnenolone concentration in XBD173 and Ro5-4864 treated 
BV-2-TSPOknock-down cells (SCR_XBD: 14.30 ng/ml; KD_XBD: 5.07 ng/ml; ttest; 
p>0.001), (SCR_Ro: 5,96 ng/ml; KD_XBD: 4,74 ng/ml; ttest; p>0.05) when compared 
to XBD173 and Ro5-4864 treated BV-2scramble cells supports the hypothesis of a 
functional role for TSPO in neurosteroidogenesis. Moreover, it indicates that XBD173 
is a direct TSPO agonist, showing a putative TSPO-specific effect. 
5.4.1 Neurosteroid quantification with GC/MS analysis 
The pregnenolone concentration was determined in either BV-2-TSPOknock-down cells 
or in BV-2-TSPOscramble cells after treatment with XBD173 (10 µM), PK11195 (100 
nM), Ro5-4864 (100 nM) and LPS (100 ng/ml) with GC/MS analysis. THDOC and 
allopregnanolone concentration was also determined, however the results 
were below the detection limit of 5 ng/ml. Four independent experiments were 
performed in duplicates and normalized to the internal standard pregnenolone-d4. 
The average and the standard error of the mean are shown in figure 10a-c.   
XBD173 treated BV-2-TSPOscramble cells show a significantly increased pregnenolone 
concentration (19.47 ng/ml) (t-test: p=0.048) when compared to solvent control 
(10.56 ng/ml) (figure 10a). All other treatments induced a decrease in pregnenolone 
concentration of BV-2scramble cells (figure 10a): LPS treated cells show a significant 
decrease in pregnenolone concentration (6.74 ng/ml) (t-test: p=0.029) when 
compared to BV-2scramble solvent control. PK11195 and Ro5-4864 treatment led to 
decrease in pregnenolone concentration (PK11195: 8.52 ng/ml and Ro5-4864: 9.30 
ng/ml) without any significance when compared to BV-2scramble solvent control (figure 
10a).  
XBD173, PK11195, Ro5-4864 and LPS treated BV-2-TSPOknock-down cells show no 
significant changes in pregnenolone concentration after drug treatment when 
compared to BV-2-TSPOknock-down solvent control (figure 10b). 
BV-2-TSPOknock-down cells show a significant decrease in pregnenolone concentration 
(5.25 ng/ml; t-test: p<0.05) when compared to BV-2scramble cells (10,56 ng/ml), (figure 
10c) which is in line with my hypothesis as a functional role for TSPO in 
neurosteroidogenesis. The direct comparison of XBD173, PK11195, Ro5-4864 and  
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Figure 10 GC/MS Quantification of neuroactive steroids and pregnenolone. Pregnenolone 
concentration was determined in either cell culture supernatants of BV-2scramble (SCR) cells or in 
BV-2-TSPOknock-down (KD) cells after treatment with XBD173 (10µM), PK11195 (100nM), Ro5-4864 
(100nM) and LPS (100ng/ml). Levels of THDOC and allopregnanolone were also determined. 
Four independent experiments were performed in duplicates and normalized to the internal 
standard pregnenolone-d4. The average and standard error of the mean are shown in [ng/ml]. 
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LPS treated BV-2-TSPOknock-down cells and BV-2scramble cells are shown in figure 10c. 
A significant decrease of pregnenolone concentration in XBD173 treated BV-2-
TSPOknock-down cells (WT_XBD: 19.47 ng/ml; KD_XBD: 5.53 ng/ml; ttest; p>0.05), 
when compared to XBD173 treated BV-2scramble cells supports the hypothesis of a 
functional role for TSPO in neurosteroidogenesis. Moreover, it indicates XBD173 as a 
direct TSPO agonist which mediates a TSPO-specific effect. 
5.5 TSPO ligand pharmacology in relationship to neurosteroidogenesis  
The pharmacological profile of three well established TSPO ligands XBD173, 
etifoxine and diazepam with regard to TSPO binding affinity, TSPO expression and 
pregnenolone concentration was analyzed to figure out any clear relationship to the 
TSPO function in neurosteroidogenesis. 
5.5.1 Analysis of TSPO protein expression after TSPO ligand treatment 
BV-2wild-type cells were treated with XBD173, etifoxine or diazepam as described 
previously to show if the protein expression after TSPO ligand incubation has any 
significant effect which may correlate with a significant effect in the TSPO function of 
neurosteroid synthesis. The effect of 24 h drug incubation on TSPO protein 
expression in BV-2 cells is presented in figure 11.  
 
 
 
Figure 11 TSPO protein expression in BV-2wild-type cells after ligand administration and 24 h 
incubation. Seventeen independent experiments were performed, results are presented as 
arbitrary units (rU), normalized to β-actin and in relation to solvent control. 
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XBD173, etifoxine and diazepam significantly increased TSPO protein expression 
already at the lowest concentration applied when compared to solvent control (t-test; 
p<0.05). However, there were no significant concentration-related effects on TSPO 
expression after XBD173, etifoxine or diazepam treatment (ANOVA; F = 1.452, df = 
3, 230, p = 0.228). Moreover, there was no significant difference between the 
different drugs on TSPO protein expression (ANOVA; F = 1.284, df = 2, 230, p = 
0.279) and no significant interaction effect between the different compounds and 
concentrations used (ANOVA; F = 0.728, df = 6, 230, p = 0.627). Within the used 
concentrations (0.1 µM to 10 µM) the drugs did not show toxic effects. 
5.5.2 Analysis of the TSPO binding affinity after TSPO ligand treatment 
The binding affinity of XBD173, etifoxine and diazepam to TSPO in BV-2wild-type cells 
was analyzed by means of a competitive [3H]PK11195 radioligand binding assay to 
figure out if there is a correlation of the ligand binding affinity and the ligand induced 
TSPO function. The binding affinity of each ligand is shown as IC50, which shows the 
concentration of a drug at 50% of [3H]PK11195 displacement (figure 12).  
 
 
 
Figure 12 Displacement of [
3
H]PK11195 binding to TSPO by XBD173, etifoxine, or diazepam.  
Data represent the mean values of three independent experiments (each measured in 
triplicate). The competition of [
3
H]PK11195 binding by increasing concentrations of incubated 
compounds in logarithmic representation is shown.  
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IC50 values appeared sufficient to compare binding affinities of these TSPO ligands, 
because experimental conditions were identical for all three TSPO ligands. XBD173 
showed the highest binding affinity (IC50 of 0.16 nM), diazepam showed an 
intermediate IC50 of 1.07 nM and etifoxine had the lowest binding affinity by an IC50 of 
22.78 nM.  
5.5.3 Neurosteroid synthesis 
Because the anxiolytic efficacy of TSPO ligands is assumed to be determined by 
their potency to enhance neurosteroid synthesis, pregnenolone levels after treatment 
with XBD173, etifoxine or diazepam were measured in BV-2wild-type cells by means of 
ELISA. Effects of drug incubation on pregnenolone synthesis in BV-2 cells are 
presented in figure 13. Etifoxine turned out to be the most potent compound, which 
significantly upregulated pregnenolone levels dose-dependently (ANOVA; F = 9.471, 
df = 3, 95, p<0.001). However, upon treatment with the highest concentration (10 
µM), there was a marked drop of pregnenolone synthesis. Also, XBD173 showed a 
significant enhancement of pregnenolone synthesis with a significant dose-response-
relationship (ANOVA; F = 3.247, df = 3, 95, p = 0.025).  Diazepam did not show a 
significant enhancement of pregnenolone synthesis at all concentrations. 
 
 
 
Figure 13 Pregnenolone concentration after 24 h treatment with XBD173, etifoxine or diazepam. 
Six independent experiments were performed and normalized to solvent control. The average 
and the standard error of the mean were calculated.  
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5.6 Ca2+ levels via FURA-2 fluorescence technique 
TSPO is assumed to be involved in Ca2+ homeostasis but only rare data is available 
about a role in regulation of cytosolic and mitochondrial Ca2+ concentration. 
Therefore, a Ca2+ imaging experiment was performed to compare Ca2+ levels in ER 
and mitochondrial of BV-2scramble (SCR) and BV-2-TSPOknock-down (KD) cells.  
5.6.1 Ca2+ imaging of BV-2scramble cells  
A typical experimental pattern of BV-2scramble cells responding to ATP and FCCP can 
be seen in figure 14. The According to experimental pattern, FURA-2 based Ca2+ 
imaging was performed on BV-2scramble cells and BV-2-TSPOknock-down cells after 24 h 
incubation with 10 µM XBD173, 100 nM PK11195, 100 nM Ro5-4864 and 100 ng/ml 
LPS. FURA-2 fluorescence ratio values (Fratio(340/380) values) from the regions of 
interest (ROIs) were analyzed (figure 15) and presented as arbitrary units (rU).  
 
 
 
Figure 14 A typical response curve of BV-2scramble cells to ATP (100 μM) and FCCP (10µM) 
application. BV-2scramble cells were stimulated using ATP (100µM), to release Ca
2+
 from 
intracellular ER stores into the cytosol. ATP was applied for 60 seconds (red arrow). Cells were 
perfused 4 additional minutes with ringer, before they were stimulated with FCCP (10µM), 
which leads to an efflux of Ca
2+
 from mitochondrial stores. FCCP was applied for 60 seconds, 
(blue arrow). The green graph shows the ratio of the FURA-2 fluorescence signals (340/380nm) 
in relative units [rU] plottet against the time in minutes [min]. Light green bars show the 
negative and positive standard deviation of each measured value.  
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The fluorescence ratios of basal relative Ca2+ concentration (ΔFratio(340/380)basal) were 
measured in BV-2scramble (dark green) and BV-2-TSPOknock-down cells (light green) 
during ringer perfusion and normalized to solvent control. Results are presented in 
figure 15a.  
 
 
 
Figure 15 FURA-2 based Ca
2+
 imaging was performed on BV-2 scramble and BV-2-TSPOknock-
down cells after 24 h incubation with 10 µM XBD173, 100 nM PK11195, 100 nM Ro5-4864 and 100 
ng/ml LPS. FURA-2 fluorescence ratio values are presented as arbitrary units (rU). 
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The fluorescence ratios after 100 μM ATP application (ΔFratio(340/380)ATP) were also 
examined in BV-2scramble (dark red) and BV-2-TSPOknock-down cells (light red)  and 
normalized to basal ratio. Results are presented in figure 15b and show the Ca2+ 
which is released from ER stores. The FCCP-induced fluorescence ratios 
ΔFratio(340/380)FCCP were investigated in in BV-2scramble (dark blue) and BV-2-TSPOknock-
down cells (light blue) after FCCP application and normalized to basal ratio. The results 
are presented in figure 15c, and show the Ca2+ which is released from mitochondrial 
stores.  
The basal fluorescence ratios ΔFratio(340/380)basal (figure 15a) showed no significant 
changes in the basal Ca2+ signal of BV-2scramble cells (XBD173: 0.99; PK11195: 0.99; 
LPS: 0.86; Ro5-4864: 1.00) compared to BV-2scramble solvent control (SCR: 1.06) and 
of BV-2-TSPOknock-down cells (XBD173: 0.96; PK11195: 1.05; LPS: 0.91; Ro5-4864: 
1.04) when compared to BV-2-TSPOknock-down solvent control (SCR: 0.99) after drug 
treatment.  
The ATP-induced Ca2+ signal ΔFratio(340/380)ATP (figure 15b; dark red) in BV-2scramble 
cells was increased in Ro5-4864 treated BV-2scramble cells (0.43), but without any 
significance when compared to BV-2 scramble solvent control (0.37). XBD173  and 
PK11195 treatment of BV-2scramble cells lead to a slightly, non-significantly decreased 
Ca2+ signal (XBD173: 0.32; PK11195: 0.33), compared to BV-2scramble solvent control. 
Only LPS treated BV-2scramble cells showed a significant decreased Ca
2+ signal (0.22; 
t-test: p=0.021) compared to BV-2scramble solvent control. 
The ATP-induced Ca2+ signal ΔFratio(340/380)ATP in BV-2-TSPOknock-down cells (figure 15b; 
light red) was non-significantly increased in LPS treated BV-2-TSPOknock-down cells 
(LPS: 0.41) when compared to BV-2-TSPOknock-down solvent control (KD: 0.31). 
XBD173 (0.23; t-test: p<0.05) and PK11195 (0.20; t-test: p<0.001) treatment in BV-2-
TSPOknock-down cells led to significantly decreased ATP-induced Ca
2+ signals when 
compared to BV-2-TSPOknock-down solvent control. Only Ro5-4864 treatment showed 
no changes of the ATP-induced Ca2+ signal in BV-2-TSPOknock-down cells compared to 
BV-2-TSPOknock-down solvent control.  
The FCCP-induced Ca2+ signal ΔFratio(340/380)FCCP (figure 15c; dark blue) in BV-2scramble 
cells showed a high Ca2+ signal in Ro5-4864 treated BV-2scramble cells, which is 
significantly increased when compared to BV-2scramble solvent control (Ro5-4864: 
0.48; SCR solvent control: 0.22; t-test: p<0.001). The FCCP-induced Ca2+ signal in 
XBD173, PK11195 and LPS treated BV-2scramble cells was low and significantly 
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decreased when compared to BV-2scramble solvent control (XBD173: 0.19; PK11195: 
0.18; LPS: 0.14; t-test: p<0.001). 
The FCCP-induced Ca2+ signal ΔFratio(340/380)FCCP (figure 15c; light blue) in BV-2-
TSPOknock-down cells was significantly decreased in XBD173 (0.15; t-test: p<0.001), 
PK11195  (0.16; t-test: p<0.001) and LPS (0.06; t-test: p<0.01) treated BV-2-
TSPOknock-down cells when compared to BV-2-TSPOknock-down solvent control (0.29).  
Only Ro5-4864 treated BV-2-TSPOknock-down cells did not show any difference in the 
FCCP-induced Ca2+ signal when compared to BV-2-TSPOknock-down solvent control. 
Summarizing this experiment, the relative basal cytosolic Ca2+ concentration is 
unaltered BV-2-TSPOknock-down cells when compared to BV-2scramble cells and the drug 
treatment did neither affect the relative basal cytosolic Ca2+ concentration in BV-2 
scramble cells nor in BV-2-TSPOknock-down cells (figure 15a).
  
However, the ATP-induced Ca2+ signal (indirect determination of ER Ca2+ release) 
was increased in Ro5-4864 treated BV-2scramble cells, but decreased in XBD173, 
PK11195 and LPS treated BV-2scramble cells. The same pattern had become 
appearent with the FCCP-induced Ca2+ signal (indirect determination of mitochondrial 
Ca2+ release) in BV-2scramble cells: it was increased in Ro5-4864 treated BV-2scramble 
cells, but decreased in XBD173, PK11195 and LPS treated BV-2scramble cells. It is 
conceivable, that a high relative ER- Ca2+ concentration correlates with high relative 
mitochondrial Ca2+ concentration and vice versa. This assumption would lead to a 
direct ER-mitochondrial link – the mitochondrial associated membranes (MAM) which 
allow a rapid transmission of Ca2+ signals between the ER and mitochondria thereby 
regulating mitochondrial bioenergetics (van Vilet et al., 2014). Another possibile 
explanation is a drug induced altered Ca2+ storage capacity in ER and mitochodria:  
XBD173, PK11195 and LPS treatment appears to reduce Ca2+ storage capacity in 
mitochondria and ER of BV-2scramble cells and Ro5-4864 treatement might lead to an 
increased Ca2+ storage capacity in mitochondria and ER of BV-2scramble cells. 
Furthermore, it was neccesary to proof whether the obtained effects were TSPO 
mediated. Therefore, the same experiment was performed with BV-2-TSPOknock-down 
cells. 
Direct comparison of the ATP-induced Ca2+ signal (indirect determination of ER Ca2+ 
release) and of the FCCP-induced Ca2+ signal (indirect determination of mitochondrial 
Ca2+ release) in BV-2scramble cells and BV-2-TSPOknock-down cells showed no significant 
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differences. This assumes, that a knock-down of TSPO has no effect on the ATP-
induced and FCCP-induced Ca2+ signal in BV-2 mouse microglia cells.  
XBD173 and PK11195 treatment led to a decreased ATP-induced and to a 
decreased FCCP-induced Ca2+ signal in BV-2-TSPOknock-down cells. This result 
underlines the prior statement of a drug induced alteration of Ca2+ storage capacity in 
mitochondria and ER, which is unrelated to TSPO. 
Furthermore, the ATP-induced Ca2+ signal was decreased after LPS treatment in BV-
2scramble cells, but increased in LPS treated BV-2-TSPOknock-down cells. This indicates a 
Ca2+ regulating role of TSPO during inflammation caused by LPS. LPS treated TSPO 
knock-down cells and BV-2scramble cells showed a significantly decreased FCCP-
induced Ca2+ signal which indicates a TSPO independent effect. 
A similar result was observed after Ro5-4864 treatment. The ATP-induced and the 
FCCP-induced Ca2+ signal was reduced in BV-2-TSPOknock-down cells compared to 
BV-2scramble cells. This observation is in favor of the hypothesis` TSPO related effect.  
5.7 Analysis of the mitochondrial membrane potential 
BV-2scramble cells were loaded with the JC-1 dye as described in materials and 
methods. If the mitochondrial membrane potential is low (less hyperpolarized), JC-1 
is predominantly a monomer yielding in green fluorescence. If the mitochondrial 
membrane potential is high, the dye aggregates which yields in a red to orange 
colored emission. Therefore, a decrease in the aggregate fluorescent count was an 
indicator for depolarization of the mitochondrial membrane potential whereas an 
increase was an indicator for hyperpolarization of the mitochondrial membrane 
potential.  
The basal values in figure 16a show a significantly increased basal mitochondrial 
membrane potential in XBD173 treated cells (0.33; t-test: p<0.05), when compared to 
solvent control (0.30). PK11195, Ro5-4864 and LPS treatment resulted in a lower 
mitochondrial membrane potential, which is significantly decreased when compared 
to solvent control (PK11195: 0.21; t-test: p<0.001; Ro5-46864: 0.18; t-test: p<0.001; 
LPS: 0.15; t-test: p<0.001). BV-2-TSPOknock-down cells showed also a significantly 
decreased mitochondrial membrane potential (0.25; t-test, p<0.01) when compared 
to BV-2scramble solvent control.   
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Figure 16 BV-2-TSPOknock-down cells and BV-2scramble cells after 24h treatment with XBD173 (10 
µM), PK11195 (100 nM), Ro5-4864 (100 nM) and LPS (100 ng/mL) were analyzed. JC-1 
fluorescence ratios (JC-1 ratio (aggregate/monomer)) were detected, normalized to solvent control and 
are presented in arbitrary units [rU] (a) / percent over solvent control (b).   
 
A decrease in the fluorescence ratio is an indicator for depolarization (low 
mitochondrial membrane potential ) whereas an increase of fluorescence ratios is 
an indicator for hyperpolarization (high mitochondrial membrane potential ). In BV-
2scramble cells, the basal  was increased in XBD173 treated cells but decreased in 
PK11195, Ro5-4864 and LPS treated cells and in BV-2-TSPOknock-down cells (without 
any treatment). According to Piccoli et al. the highest in XBD173 treated BV-
2scramble cells indicates a high energetic status and thereby a low energy demand of 
these cells (Piccoli et al., 2006). PK11195, Ro5-4864 and LPS treatment and as well 
BV-2-TSPOknock-down cells showed a constantly lower , indicating a lower energetic 
status and a higher energy demand of these cells when compared to the BV-2scramble 
solvent control.  
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5.8  The bioenergetic profile of intact BV-2scramble cells  
Cell respiration was analyzed in intact BV-2scramble cells and after 24 h treatment with 
either 10 µM XBD173, 100 nM PK11195, 100 nM Ro5-4864 or 100 nM LPS with the 
Seahorse Biosciences Extracellular Flux (XFp) Analyzer as described in material and 
methods. A typical Seahorse measurement pattern (figure 17) was used to analyze 
the bioenergetic function of BV-2scramble cells. 
 
 
 
Figure 17 The oxygen consumption rate (OCR) of BV-2scramble cells was analyzed with the 
Seahorse Bioscience XFp flux analyzer. Following the manufactures recommendations of the 
Seahorse Bioscience mito stress test, the basal oxygen consumption rate (A), the non-
phosphorylating resting state (LEAK respiration) (C), the ATP turnover (B), the maximal 
respiration (D) and the Spare respiratory capacity (E) was analyzed in intact BV-2 scrambe cells 
after 24h treatment with various drugs. 
 
The obtained OCR data for basal respiration (A), uncoupled, non-phosphorylating 
LEAK respiration (B), ATP turnover (C), maximal respiration (D) and spare 
respiratory capacity (E) are shown in figure 18 a-d reported as OCR in pmol per 
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minute. In the simplified representation of the data (figure 18e), respiratory changes 
in each experimental setup are shown in ratio solvent control (100% baseline).  
 
 
 
Figure 18 The basal respiration (A), the leak respiration (B), the calculated ATP turnover (C), 
the maximal respiration (D) and the spare respiratory capacity (E) were analyzed in drug 
treated  BV-2scramble cells and normalized to BV-2scramble cells solvent control. 
 
The basal respiration in XBD173 (267.9 pmol/min), PK11195 (264.2 pmol/min) and 
Ro4-45864 (218.6 pmol/min) treated BV-2scramble cells was enhanced when compared 
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to BV-2scramble solvent control (205.1 pmol/min), XBD173 (t-test: p< 0.05) and 
PK11195 (t-test: p< 0.05) increase was significant (figure 18e).  
Then, oligomycin was applied to inhibit the ATP-synthase and induce the non-
phosphorylating, uncoupled leak respiration of the cells. XBD173 (48.7 pmol/min; t-
test: p>0.001) and PK11195 (49.3 pmol/min; t-test: p>0.001) treated cells show a 
significantly increased leak respiration, whereby Ro5-4864 (39.3 pmol/min) treatment 
led to a non-significant increase when compared to solvent control (36.5 nmol/min).  
On the basis of these oligomycin-induced leak respiration results ATP turnover can 
be calculated. This calculation led to a significant increase of ATP turnover in both, 
XBD173 (219.2 pmol/min; t-test: p>0.5) and PK11195 (214.9 pmol/min; t-test: 
p<0.05) treated cells and to a non-significant increase of ATP turnover after Ro5-
4864 (179.3 pmol/min) treatment when compared to solvent control (168.6 pmol/min).  
Following the protocol procedure, FCCP as an uncoupling agent collapses the proton 
gradient and disrupts the mitochondrial membrane potential resulting in an unlimited 
electron flow through the ETC. This leads to an increase of electron flow and thereby 
an increase in oxygen consumption. XBD173 treatment led to a significant decrease 
in maximal respiration (449.2 pmol/min; t-test; p<0.001), whereby PK11195 (525.1 
pmol/min; t-test: p<0.01) treatment provides a significant increase in maximal 
respiration when compared to solvent control (499.5 pmol/min). This presumably 
leads to a higher maximal respiratory capacity of XBD173 treated cells and a lower 
maximal respiratory capacity of PK11195 treated cells compared to solvent control. 
No significant changes in maximal respiration were detected Ro5-4864 (497.2 
pmol/min) treated cells compared to solvent control.  
The spare respiratory capacity is defined as maximal respiratory capacity minus 
basal respiratory capacity. All treated BV-2scramble cells led to a lower spare respiratory 
capacity (PK11195: 310.2 pmol/min; Ro5-4864: 317.9pmol/min) compared solvent 
control (330.9 pmol/min), however only XBD173 treated BV-2scramble cells showed a 
significant decrease (229.9 pmol/min; t-test; p<0.001).  
5.9 The bioenergetic profile of intact BV-2scramble and BV-2-TSPOknock-down cells 
In order to show a direct involvement of TSPO in mitochondrial respiration, intact BV-
2scramble cells and BV-2-TSPOknock-down cells were analyzed by using the Seahorse 
Biosciences Extracellular Flux (XFp) Analyzer as described in materials and 
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methods. The method allows the real-time analysis of bioenergetic changes 
depending on the presence or absence of TSPO in the cells.  
 
 
 
Figure 19 The bioenergetic profile of BV-2-TSPOknock-down cells and BV-2scramble cells.  
(a)-(b) Basal respiration (A), non-phosphorylating LEAK respiration (B), ATP turnover (C), 
maximal respiration (D) and spare respiratory capacity (E) are presented as OCR in pmol per 
minute. (c) Respiratory changes in BV-2-TSPOknock-down cells statistically compared to BV-
2scramble cells.  
 
The OCR data for basal respiration (A), non-phosphorylating LEAK respiration (B), 
ATP turnover (C), maximal respiration (D) and spare respiratory capacity (E) are 
shown in figure 19a and 19b presented as pmol per minute. In figure 19c respiratory 
changes in BV-2-TSPOknock-down cells are statistically compared to BV-2scramble cells. 
The basal respiration (A) of both, BV-2scramble (137.6 pmol/min) and BV-2-TSPOknock-
down cells (136.4 pmol/min) showed no significant differences. After oligomycin 
application, the remaining cell respiration reflected the non-phosphorylating leak 
respiration (B) of the cells. The leak respiration of BV-2scramble cells (32.1 pmol/min) 
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did not show significant changes when compared to the leak respiration of BV-2-
TSPOknock-down cells (27.7 pmol/min). Then, the ATP turnover (C) was calculated as 
the difference between basal respiration and leak respiration. The ATP turnover of 
BV-2-TSPOknock-down cells (108.7pmol/min) did not differ significantly from the one of 
BV-2scramble cells (105.5 pmol/min). The following FCCP injection led to dissipation of 
the mitochondrial membrane potential. As a result, BV-2-TSPOknock-down cells showed 
a significantly increased maximal respiration (D) (589.4 pmol/min; t-test: p<0.001) 
compared to BV-2scramble cells (537.9 pmol/min). Thus, BV-2-TSPOknock-down cells 
appear to have a higher maximal respiratory capacity when compared to BV-2scramble 
cells. The spare respiratory capacity (E) of BV-2-TSPOknock-down cells (480.7 
pmol/min; t-test: p<0.05) is significantly higher than the one of BV-2scramble cells (432.5 
pmol/min).   
5.10 High resolution respirometry in permeabilized cells    
The respiration (oxygen flux) of either 1x106 BV-2scramble or 1x10
6  BV-2-TSPOknock-down 
cells was analyzed in separated O2k-chambers and recorded in real-time using the 
Oroboros O2k oxygraph. The used SUIT protocol is visualized in figure 20. The 
routine respiration of untreated cells (A) was measured before the injection of 4 µl 
digitonin led to permeabilization of the cells, resulting in the basal respiration of 
permeabilized BV-2 cells (B). In a following step, the non-phosphorylating LEAK-
respiration was induced by adding the complex-I-linked substrates malate (0.5 mM) 
and glutamate (10 mM), but not ADP. After that, complex-I-linked oxidative 
phosphorylation (OXPHOS) capacity (C) was investigated separately by addition of a 
saturating concentration of ADP (2.5 mM). After addition of the complex-II-linked 
substrate succinate (10 mM), it was possible to analyze the combined complex-I and 
complex-II-linked OXPHOS-capacity (E). Oligomycin (ATPase synthase inhibitor) 
injection (2.5 µM) inhibited the O2 consumption until the LEAK state of respiration 
was reached, representing again the non-phosphorylating resting state when ATP 
synthase is not active (F). Further inhibition of complex-I by rotenone (0.5 μM) led to 
the measurement of complex-II-linked ETS capacity. In order to figure out whether 
there were further oxygen-consuming processes, complex-III was inhibited by 
antimycin A (2.5 µM). The resulting residual oxygen consumption (ROX) reflects 
oxygen consumption from undefined sources (Gnaiger, 2014).  
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The statistical analysis of the high resolution respirometry experiment of 106 BV-2-
TSPOknock-down cells and 10
6 BV-2scramble cells is shown in figure 21 according to the 
SUIT protocol (figure 20). 
 
 
 
Figure 21 The bioenergetic profile of BV-2-TSPOknock-down cells (light grey bars) compared to BV-
2scramble ells (dark grey bars). The used SUIT protocol is described in figure 20. The analysis was 
performed using the same amount of BV-2scramble and BV-2-TSPOknock-down cells.  
 
BV-2-TSPOknock-down cells (light grey bars) show a routine respiration comparable to 
BV-2scramble cells (dark grey bars). OXPHOS, LEAK and ETC respiratory capacity are 
increased in BV-2-TSPOknock-down cells (OXPHOS: 157.5 pmol/s*mL; LEAK: 35.7 
pmol/s*mL; 184.0 pmol/s*mL) when compared to BV-2scramble cells (OXPHOS: 123.9 
pmol/s*mL; LEAK: 25.1 pmol/s*mL; 144.0 pmol/s*mL), whereby the increase of 
OXPHOS capacity is significant (t-test, p<0.05). 
A specific OXPHOS examination of permeabilized cells was performed in 106 BV-2-
TSPOknock-down cells and 10
6 BV-2scramble cells (figure 21). BV-2-TSPOknock-down cells 
showed a higher complex-I (43.5 pmol/s*mL) and complex-II (114.1 pmol/s*mL) -
linked OXPHOS capacity than BV-2scramble cells (cI: 33.2 pmol/s*mL; cII: 90.7 
pmol/s*mL). However, only the total OXPHOS (sum of complex-I and complex-II-
linked OXPHOS capacity) showed a significant (t-test; p<0.05) increase in BV-2-
TSPOknock-down cells (157.5 pmol/s*mL) compared to BV-2scramble cells (123.9 
pmol/s*mL).  
Summarizing this experiment, the presence of TSPO (BV-2scramble) leads to a lower 
ATP utilization and a lower oxidative phosphorylation, which is decreased in both to 
complex-I and complex-II respiratory capacity. Regarding the mitochondrial 
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membrane potential experiments, BV-2scamble cells showed a higher energy state of 
the cell indicating a reduced energy demand which indeed correlates with the lower 
ATP utilization.  
 
 
 
Figure 22 A specific OXPHOS examination of permeabilized cells was performed in 10
6 
BV-2-
TSPOknock-down cells and 10
6
 BV-2scramble cells.  
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6 Discussion  
TSPO is a highly conserved protein, which is expressed in every species (Li et al., 
2015) from bacteria to mammals (Yeliseev & Kaplan, 1995). Due to its expression in 
steroid synthesizing cells and the given high affinity cholesterol binding property, 
numerous studies have been attempting a putative functional role of TSPO in 
cholesterol translocation and neurosteroidogenesis (Papadopoulos et al., 1997), (Li 
et al., 2015). Moreover, TSPO has been suggested to be a component of the mPTP 
(McEnery et al., 1992), thereby regulating mPTP opening. Recent studies now 
question the role of TSPO in steroidogenesis, its involvement in the mPTP and the 
physiological role related to PPIX and heme biosynthesis (Zhao et al. 2016), 
(Morohaku et al., 2014), (Tu et al.,  2014), (Banati et al., 2014), (Šileikytė et al., 
2014), (Selvaraj & Stocco, 2015), (Gatliff & Campanella, 2016), (Selvaraj & Tu, 
2016). Whereby recent studies are based on genetic TSPO deletions, the early 
studies only used TSPO ligands to detect any pharmacological effects, which now 
are purported to be non-specific or related on secondary responses unrelated to 
TSPO (Tu et al., 2015), (Šileikytė et al., 2014). Therefore, it seems that the precise 
physiological and pathological function of TSPO is still unknown (Selvaraj & Stocco, 
2015), (Gatliff & Campanella, 2016), (Selvaraj & Tu, 2016).  
It is a common assumption that ancient, evolutionarily highly conserved gene should 
be essential for the proper regulation of precise, fundamental physiological processes 
(McLean et al., 2011). Regarding the possible new role of TSPO in mitochondrial 
metabolism, neurosteroidogenesis and involvement in ROS generation (Gut et al., 
2015), (Selvaraj & Tu, 2016), (Selvaraj & Stocco, 2015), it is still necessary and 
indispensable to work with genetic TSPO deletions, avoiding any artefacts or 
secondary effects of TSPO ligands unrelated to TSPO. To get deeper insight in this 
relationship of TSPO and neurosteroid synthesis, and the role of TSPO in brain 
mitochondrial metabolism with regard to calcium homoeostasis, respiration and 
mitochondrial membrane potential a BV-2-TSPOknock-down model was performed and 
used in this thesis.  
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TSPO is a regulatory protein of neurosteroidogenesis 
The role of TSPO in steroidogenesis is still a frequently discussed and examined 
topic. Since recent in vivo and in vitro studies using TSPO knock-out models have 
been refuting its role in steroidogenesis, there is still an open question of TSPO 
involvement in neurosteroidogenesis (Selvaraj & Tu, 2016). The brain is able to 
produce neurosteroids de novo to regulate neuronal function (Schumacher et al., 
2000). In contrast to steroidogenesis, neurosteroidogenesis is not hormone-
regulated.  Many studies demonstrated TSPO ligands modulating brain 
neurosteroidogenesis (Papadopoulos et al., 2014), (Selvaraj & Tu, 2016). 
Neurosteroids are known to evoke anti-inflammatory effects in the brain (Stoffel-
Wagner, 2003), (Pinna et al., 2006). Induction of neurosteroid synthesis in the brain 
by TSPO ligands has already been used to reduce neuropsychiatric disease 
symptoms in vivo (Rupprecht et al., 2010). There is still an open frame of TSPO 
involvement in neurosteroidogenesis (Selvaraj & Tu, 2016). And therefore, in order to 
pursue this issue, the function of TSPO regarding neurosteroid synthesis was 
analyzed in a comparative study between BV-2scrambled cells and BV-2-TSPOknock-down 
cells. 
Neurosteroidogenesis in BV-2-TSPOknock-down cells 
A lentiviral TSPO knock-down was performed in BV-2 cells. Western Blot and 
immunostaining confirmed a significant downregulation of TSPO in BV-2-TSPOknock-
down cells when compared to BV-2scramble cells (figure 4 and 5). Two different 
approaches were used to quantify pregnenolone levels: an antibody-based ELISA 
and a gas chromatography/mass spectrometry approach. BV-2-TSPOknock-down cells 
showed a significant decrease in pregnenolone concentration when compared to BV-
2scramble cells after analysis with ELISA technique (figure 9c). The GC/MS technique 
analysis also showed a significant decrease in pregnenolone concentration of BV-2-
TSPOknock-down cells when compared to BV-2scramble cells (figure 10c) which is 
comparable to the ELISA results. This result supports my hypothesis that TSPO 
plays a regulatory role in neurosteroid synthesis of brain microglia cells.  
A further analysis using ELISA and GC/MS technique compared the pregnenolone 
concentration of BV-2-TSPOknock-down cells and BV-2scramble cells after 24h ligand 
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treatment (figure 9 and 10). Ligand treatment of BV-2scramble cells shows a significant 
increase of pregnenolone concentration after XBD173 treatment (figure 9a and 10a), 
assuming a TSPO-specific effect of XBD173. BV-2-TSPOknock-down cells showed no 
enhanced pregnenolone concentration after XBD173 treatment, confirming a TSPO-
specific effect of XBD173 in the regulation of neurosteroid synthesis. 
A recent study measuring steroid production via pregnenolone concentration was 
performed by Banati et al. (2014) and showed contrary results. The group was using 
whole TSPO knock-out mice to analyze the pregnenolone concentration from blood 
samples via ELISA. They obtained concentration values in a normal range of both 
TSPO knock-out samples and scramble samples without any significant differences. 
However, Banati et al. did not directly analyze the pregnenolone concentration in 
brain cells compared to my experiments based on the single use of brain microglia 
cells. The use of brain cells allows a better insight in brain neurosteroidogenesis as 
Banati could just assume by using whole blood samples. The fact that expression of 
TSPO in the brain is quite low (Daugherty et al., 2013) in ratio to the total body 
expression makes it even more difficult to have a direct correlation to the 
neurosteroidogenesis analyzed by whole blood samples.  
How do TSPO ligands influence neurosteroid synthesis? 
Regarding pregnenolone as the precursor of all neurosteroids, the question recently 
has arised whether TSPO ligands are able to modulate pregenolone production in 
brain cells. Therefore the relationship between TSPO protein expression, TSPO 
binding affinity and the resulting effect of neurosteroid synthesis was analyzed in BV-
2wild-type cells (figure 11, 12 and 13). The used TSPO ligands were chosen by their 
ability to treat anxiety disorders. Etifoxine was the first TSPO ligand with clinical 
anxiolytic effects, XBD173 exerts potent anxiolytic efficacy in animals as well as in 
humans and diazepam is a frequently prescribed anxiolytic, also binding to TSPO. 
XBD173, etifoxine and diazepam all show considerable binding affinities to TSPO in 
the [³H]PK11195 radioligand binding assay of BV-2-TSPOwild-type cells (figure 12). 
XBD173 turned out to be the ligand with the highest binding affinity, followed by 
diazepam and etifoxine. Furthermore, XBD173, etifoxine and diazepam increased the 
TSPO protein expression in BV-2-TSPOwild-type cells, but without showing a clear 
concentration-dependence (figure 11). The pregnenolone concentration was 
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significantly increased in BV-2-TSPOwild-type cells after XBD173 and etifoxine 
treatment (figure 13). As pointed out before, there is a discrepancy between the 
binding affinity of a ligand, the effect on TSPO protein expression and finally the 
enhancement of neurosteroid synthesis as a functional read out. Therefore, a certain 
TSPO binding affinity - as measured by [³H]PK1195 radio ligand displacement - does 
not necessarily allow to conclude that the compound has an effect on neurosteroid 
synthesis just due to its pharmacological affinity. 
Due to the results the impact of the selected drugs (XBD, PK11195, Ro5-4864 and 
LPS) on pregnenolone synthesis was analyzed. By the use of both GC / MS and 
ELISA technique, we could demonstrate a significant increase in pregnenolone 
concentration after 24 hours incubation with XBD173. LPS, PK11195 and Ro5-4864 
incubation led to a decreased pregnenolone concentration.  
The upregulation of the protein expression after 24h incubation with the same drugs 
XBD173, LPS, PK11195 and Ro5-4864 was confirmed by Western Blot which clearly 
demonstrates that the upregulation of TSPO is not correlating with an increase in 
pregnenolone concentration and neurosteroid synthesis.  
These results allow to conclude that the effects of TSPO ligands on neurosteroid 
synthesis are not dependent of the ligand`s binding affinity and the ligand`s protein 
expression. There is still an open question how the TSPO ligands can be arranged in 
a certain order due to its effect in pregnenolone production and thereby its effect in 
neurosteroid synthesis.  
The most recent approach from Costa et al. explains the poor relationship between 
TSPO ligand binding affinities and steroidogenic efficacies with a new finding: the 
residence time that a compound spends in contact with the target. They found a 
positive correlation between the period for which a drug interacts with TSPO and the 
compounds ability to stimulate steroidogenesis. In particular, the specific residence 
time of a TSPO ligand significantly links the steroidogenic efficacy to the dose-
response curve (combined parameter of drug potency and efficacy) (Costa, et al., 
2016).  
The aspect that TSPO ligands have additional sites of action (Šileikytė et al., 2014) 
arose with the recently critical consideration of early TSPO studies. Even more, it 
yielded in the assumption that previous pharmacological effects on steroidogenesis 
or in mPTP opening, mostly performed by the use of TSPO ligands, could be non-
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specific or unrelated to TSPO (Tu et al., 2015), (Šileikytė et al., 2014), (Selvaraj & Tu, 
2016). 
TSPO plays a role in Ca2+ homeostasis in inflammatory states 
However, there is only rare data about the role of TSPO in regulation of Ca2+ 
concentration. No genetic TSPO deletion study was performed yet regarding 
especially Ca2+ homoeostasis in brain cells. Therefore, a Ca2+ imaging experiment 
was performed to compare Ca2+ in ER and mitochondrial stores of BV-2scramble cells 
with Ca2+ in ER and mitochondrial stores of BV-2-TSPOknock-down cells.  The 
experimental set up for Ca2+ analysis in this thesis was different from actual available 
TSPO Ca2+ studies and allowed a separate analysis of the ER-released Ca2+ (ATP-
induced Ca2+ release) and the mitochondrial-released Ca2+ (FCCP-induced Ca2+ 
release). 
The relative basal cytosolic Ca2+ concentration is unaltered BV-2-TSPOknock-down cells 
when compared to BV-2scramble cells and the drug treatment did neither affect the 
relative basal cytosolic Ca2+ concentration in BV-2 scramble cells nor in BV-2-TSPOknock-
down cells (figure 15a). This indicates, that TSPO has no effect on the relative basal 
cytosolic Ca2+ concentration in BV-2 mouse microglia cells.  
However, the ATP-induced Ca2+ signal (indirect determination of ER-Ca2+ release) 
was decreased in XBD173, PK11195 and LPS treated BV-2scramble cells (figure 15b). 
The same pattern had become appearent with the FCCP-induced Ca2+ signal 
(indirect determination of mitochondrial Ca2+ release) in BV-2scramble cells, it was 
decreased in XBD173, PK11195 and LPS treated BV-2scramble cells (figure 15c). It is 
conceivable, that the drugs altered the Ca2+ storage capacity in ER and mitochodria:  
XBD173, PK11195 and LPS treatment appears to reduce Ca2+ storage capacity in 
mitochondria and ER of BV-2scramble cells. Furthermore a high ER-Ca
2+ concentration 
correlates with high mitochondrial Ca2+ concentration and vice versa. This 
assumption would lead to a direct ER-mitochondrial link – the mitochondrial 
associated membranes (MAM) which allow a rapid transmission of Ca2+ signals 
between the ER and mitochondria thereby regulating mitochondrial bioenergetics 
(van Vilet et al., 2014). Studies show that these inter-organelle connections are also 
involved in Ca2+ homeostasis, demonstrating Ca2+ transfer from ER to mitochondria 
(Rodríguez-Arribas et al., 2016).  It is conceivable, that MAMs compensate a 
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Ca2+ dysbalance between ER and mitochondria to prevent cell death (Krols et al., 
2016). Furthermore, XBD173 and PK11195 treatment led to a decreased ATP-and 
FCCP- induced Ca2+ signal in both, BV-2-TSPOknock-down cells and BV-2scramble cells. 
This suggests that the pharmacological XBD173 and PK11195 effect in ER and 
mitochondria of BV-2scramble and BV-2-TSPOknock-down cells is not TSPO-mediated. 
Rearding to the prior statement of an altered the Ca2+ storage capacity in ER and 
mitochodria, this finding underlines that XBD173 and PK11195 have additional sites 
of action, yielding in a non-specific, TSPO unrelated effect. 
The ATP-induced Ca2+ signal was decreased in LPS treated BV-2scramble cells, but 
increased in LPS treated BV-2-TSPOknock-down cells. This indicates a Ca
2+ regulating 
role of TSPO during a LPS-induced inflammation. LPS is a pro-inflammatory stimulus 
which promotes the secretion of pro-inflammatory cytokines, nitric oxide, 
and eicosanoids. Cytokines alter intracellular Ca2+ levels by depleting Ca2+ from the 
ER leading to protein misfolding and activation of the ER stress response (Yousefi et 
al., 2013), (Ramadan et al., 2011), (Brozzi et al., 2015). My result leads to the 
assumption that the presence of TSPO might be necessary to protect the cell from an 
increased ER-Ca2+ release as a response to a pro-inflammatory stimulus. 
Ro5-4864 treatment of BV-2scramble and BV-2-TSPOknock-down cells achieved no 
significant changes in the ER and mitochondrial Ca2+ levels of BV-2-TSPOknock-down 
cells, but a great increase in the ER and mitochondrial Ca2+ levels of BV-2scramble 
cells. This describes a TSPO-related enhancing effect in Ca2+ buffering and Ca2+ 
storage in both, the ER and the mitochondria after Ro5-4864 treatment.  
TSPO influences the energetic status of the cell 
According to Piccoli et al. a higher mitochondrial membrane potential () is 
correlated with a higher energy state of the cell which can be referred to a lower 
energy and a lower ATP demand of the cell. If the cell has a lower ATP demand, less 
ADP is produced. As a result, less ADP is available for the ATP synthase which 
reduces the rate of oxygen consumption. 
Vice versa, a lower mitochondrial membrane potential () correlates with a lower 
energy state of the cell, which indicates a higher energy demand. ATP is then 
hydrolyzed into ADP, whereby ADP no longer limits the activity of the ATP synthase 
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and  immediately changes. This leads to a higher oxygen consumption rate 
(Piccoli et al., 2006). 
experiments were performed using the JC-1 fluorescence dye. The highest in 
XBD173 treated BV-2scramble cells indicates a high energetic status and thereby a low 
energy demand of these cells. PK11195, Ro5-4864 and LPS treated BV-2scramble cells 
as well as BV-2-TSPOknock-down cells showed a constantly lower , indicating a lower 
energetic status and a higher energy demand of these cells compared to solvent 
control. This result indicates a reduction in the energy state of the cell, when TSPO is 
knocked down. 
Analysis of the membrane potential led to the result, that the presence of TSPO has 
a positive effect on the energy state of the cells. Recent studies indicate that TSPO 
affects mitochondrial energy homeostasis through modulation of the fatty acid 
oxidation in cell types which are necessary for lipid storage/metabolism (Tu et al., 
2016). 
Based on the information about the TSPO ability to influence energy states of the 
cells, a respiration analysis was performed to figure out if the  result correlates 
with metabolic changes. 
Respiratory analysis of intact mouse microglia cells showed a TSPO related effect 
A respiration analysis with the Seahorse XFp flux analyzer (figure 18e) showed an 
enhanced basal respiration in drug treated BV-2scramble cells when compared to BV-
2scramble solvent control. XBD173 and PK11195 treated cells showed a significantly 
increased leak respiration, which might be caused by a higher oxidative stress level 
in these cells triggered by XBD173 and PK11195. Calculating the ATP turnover, a 
significant increase was detectable in XBD173 and PK11195 treated cells. Further 
analysis obtained a significant decrease in maximal respiration of XBD173 treated 
cells and a significant increase in maximal respiration of PK11195 treated cells 
compared with solvent control. With regard to the membrane potential analysis, 
XBD173 treated BV-2scramble cells with an increased higher energy state of the 
cell) showed the expected decreased maximal respiration. Analogous, PK11195 
treated BV-2scramble cells with a decreased lower energy state of the cell) showed 
the assumed increased maximal respiration. These XBD173 and PK11195 results of 
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the mitochondrial membrane potential analysis and the respiration experiment are 
mutually supportive. 
In a separate experiment (figure 19) the respiration in intact BV-2scramble cells and BV-
2-TSPOknock-down cells were compared (figure 19c). The basal respiration, leak 
respiration and the calculated ATP turnover in both, BV-2scramble and BV-2-TSPOknock-
down cells showed no significant differences. The maximal respiration was significantly 
increased in BV-2-TSPOknock-down cells when compared to BV-2scramble cells. With 
regard to the mitochondrialmembrane potential analysis BV-2-TSPOknock-down cells 
with a lower energy state of the cell achieved the expected increased maximal 
respiration. Finally, the spare respiratory capacity was also calculated. BV-2-
TSPOknock-down cells showed an increased spare respiratory capacity when compared 
to BV-2scramble cells. This important factor, defining the vitality of the cells, also shows 
the cell’s ability to respond to stress under conditions of increased energy demand. 
Certain parameters, such as substrate delivery to the mitochondria or the functional 
capacity of the enzymes involved in ETC, are able to influence this ability of the cell. 
For future investigations it is recommended to analyze ROS production in parallel to 
the respiration. One could figure out whether an altered or lower spare respiratory 
capacity is accompanied by ROS generation. 
Respiratory analysis showed a TSPO mediated OXPHOS increase 
To gain deeper insight in the metabolism a second comparative respiration analysis 
with the Oroboros O2k (high resolution respirometry) was performed (figure 20). 
Both, BV-2scramble and BV-2-TSPOknock-down cells showed a similar routine respiration 
of non-permeabilized cells. The same result was found in the Seahorse 
measurement. OXPHOS, LEAK and ETS respiratory capacity were increased in BV-
2-TSPOknock-down cells, whereby only the enhanced OXPHOS capacity was significant 
(figure 21). Examining the OXPHOS in detail, high resolution respirometry of 
permeabilized cells was performed in BV-2-TSPOknock-down cells and BV-2scramble cells. 
A higher complex-I and complex-II-linked OXPHOS capacity was detected in BV-2-
TSPOknock-down cells when compared to BV-2scramble cells (figure 22).  
Summarizing the respiration experiments, the presence of TSPO (BV-2scramble) leads 
to a lower ATP utilization and a lower oxidative phosphorylation which is decreased 
in both, complex-I and complex-II-linked OXPHOS capacity. Regarding the 
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mitochondrial membrane potential experiments, the same cells (BV-2scamble) showed 
a higher energy state of the cell indicating a reduced energy demand which indeed 
correlates with the lower ATP utilization. The OXPHOS apparatus is the molecular 
machinery responsible for energy production, but each reduction of oxygen to water 
by aerobic respiration is accompanied by the formation of reactive intermediates, 
formerly known as ROS. Generally, complexes I and III are considered the major 
ROS sources, and complex I is considered to be the primary source of ROS in the 
brain under both physiological and pathological conditions. BV-2-TSPOknock-down cells 
show an increased OXPHOS activity which leads in an increased ATP utilization and 
thereby in a higher ROS production. It is conceivable, that the presence of TSPO is 
necessary (BV-2scramble cells), showing a reduced OXPHOS activity, leading in a 
decreased ATP utilization which finally protects the cell from alterations and cell 
death. 
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7 Conclusion 
In conclusion, the precise function of TSPO 18 kDa is still under investigation. 
However, my results in this thesis represent a basic characterization of the role of 
TSPO in mitochondrial brain metabolism. The lentiviral TSPO knock-down in BV-2 
mouse microglia cells pointed to a significant influence of TSPO on neurosteroid 
synthesis which was demonstrated by the use of two different approaches (ELISA 
and GC/MS) leading to the same results: I was able to figure out a role of TSPO in 
neurosteroidogenesis in the CNS.  But there is still an open question of how exactly 
TSPO regulates the neurosteroid synthesis. For future investigations it is 
recommended to either use global KO mice or brain-tissue-specific KO mice in order 
to gain deeper insight in the detailed mechanism of the cholesterol transport of TSPO 
in brain mitochondria. 
TSPO might play a role in Ca2+ homoeostasis. Nevertheles, the basal cytosolic Ca2+ 
level of BV-2scramble and BV-2-TSPOknock-down cells show no differences. XBD173 and 
PK11195 treatment in this thesis do not show any TSPO-related effect. But it is 
conceivable, that the influence of these drugs alter the Ca2+ storage capacity in ER 
and mitochodria of both, BV-2scramble and BV-2-TSPOknock-down cells. Furthermore, LPS 
treatment resulted in a decreased ATP-induced Ca2+ signal in BV-2scramble cells, but 
increased ATP-induced Ca2+ signal BV-2-TSPOknock-down cells. This indicates a Ca
2+ 
regulating role of TSPO during inflammation (caused by LPS). LPS is a pro-
inflammatory stimulus which promotes the secretion of pro-
inflammatory cytokines, nitric oxide, and eicosanoids. Cytokines alter intracellular 
Ca2+ levels by depleting Ca2+ from the ER leading to protein misfolding and activation 
of the ER stress response (Yousefi et al., 2013), (Ramadan et al., 2011), (Brozzi et 
al., 2015). My result leads to the assumption that the presence of TSPO might be 
necessary to protect the cell from an increased ER Ca2+ release as a response to a 
pro-inflammatory stimulus. Ro5-4864 treatment achieved no significant changes in 
the ER and mitochondrial Ca2+ levels of BV-2-TSPOknock-down cells, but a great 
increase in the ER and mitochondrial Ca2+ levels of BV-2scramble cells. This describes 
a TSPO-related increased effect in Ca2+ buffering and Ca2+ storage in both, the ER 
and the mitochondria after Ro5-4864 treatment. It has not yet been finally clarified 
which role TSPO plays in the Ca2+ homoeostasis therefore it should be in the focus of 
further investigations.  
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Summarizing the respiration analysis and the mitochondrial membrane potential 
experiment these results indicate that the presence of TSPO increases or probably 
stabilizes the energy state of the cell, thereby regulating the energy demand of the 
cell. The following lower ATP utilization results in lower ROS production, which 
protects the cell from alterations and cell death. 
Based on the data presented in this thesis, TSPO influences the mitochondrial 
metabolism of brain cells, which may be important to control a metabolic dysfunction 
by physiological modulation. For this reason TSPO is discussed as a regulatory 
protein and it should be given more attention to TSPO and its regulatory efficacy in 
mitochondrial metabolism, neurosteroidogenesis and ROS protection for a putative 
protective role against oxidative stress and mitochondrial metabolic dysfunction. 
Furthermore, TSPO is located in the OMM, which is the cytosolic/mitochondrial 
interface that makes TSPO more accessible as another target / other proteins located 
within the mitochondrial matrix. This advantage makes TSPO a great 
pharmacological target for further investigation. 
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